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Abstracts
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The Results of the Best Trials Influencing More 
Recent Guidelines on Therapeutic Behaviour
G.F. Gensini, B. Dilaghi

The results of the “good quality” trials represent the basis of guide-
lines on therapeutic behaviour. Observational studies, Randomized 
Controlled Trials (RCTs) and Systematic overviews all contribute 
to formulate guidelines. The development of guidelines represents a 
complex path leading a clinical observation, through its challenge and 
thorough evaluation in large populations, to ultimately result in an 
appropriate therapeutic approach for the individual patient.
The classification of the results from a randomised, controlled 
study only as statistically “strong” or “weak” appeared unsatisfactory 
for the actual practice. It was necessary to consider the strength of 
the evidence, the methodological quality of the studies, the external 
validity, by applying a “considered judgment” on the whole amount 
of the data. The direct applicability of the results of a study to the 
target population addressed by the guidelines was considered as well. 
The classification of the strength of evidence and the grades of rec-
ommendations was derived from a methodology developed by inte-
grating the principles of the SIGN (Scottish Intercollegiate Guideline 
Network)1 with the statistical considerations on alpha and beta error 
size suggested by the CEBM (Centre for Evidence-Based Medicine)2 
methodology. This methodology was used in the Italian Guidelines 
on Stroke4 (in the 3rd, 4th, and 5th editions). The development of these 
guidelines has been a collaborative process, involving a multidisci-
plinary working group, named the “SPREAD Collaboration” (Stroke 
PREvention and Awareness Diffusion), in which at present 36 dif-
ferent professional organisations and two patients’ associations are 
represented. A dedicated task force and an editorial board are respon-
sible for coordinating and reviewing the texts progressively produced 
and processed. Since 1998, when works officially started, five ver-
sions were released at two-year intervals thanks to multidisciplinary 
cooperation in the processing phase and in the consensus achieve-
ment performed by the Rand method. Finally the ultimate versions 
were submitted for approval to the medical associations involved. 
The aim of these guidelines is to provide recommendations about 
the best management of acute stroke and the primary and secondary 
prevention of stroke in clinical practice. The sources of evidence to 
formulate these recommendations have been the Cochrane Database 
of Systematic Reviews and electronic medical literature databases 
(e.g. MEDLINE), as well as data from both Italian and international 
researches directly available to the experts involved in the guide-
lines formulation. Documented consensus on developing topics 
was also taken into account. The recommendations are judged valid 
when they: 1) explicitly consider all the important steps of the clini-
cal decision making process and the relevant outcomes; 2) identify 
the best evidence concerning stroke treatment and prevention, and 
critically evaluate its reliability; 3) identify and take into account the 
preferences of the involved subjects concerning the outcomes of the 
decisions taken3.
There is a similar approach about treatment of acute ischemic 
stroke (IS) in 5th edition of Italian guidelines and the more recent 
Antithrombotic and thrombolitic therapy 8th ed. ACCP Guidelines 
2008 (tab. 1)4.
Table 1 Recommendations on acute IS treatment
SPREAD 5th edition ACCP guidelines 8th edition
R 10.2 The treatment 
with intravenous r-tPA 
(0.9 mg/kg, maximum 90 
mg, with 10% of the dose 
given as a bolus followed 
by an infusion lasting 60 
min) is recommended 
within 3 h of onset of IS. 
Grade A
1.1.1.  For eligible patients we recommend 
administration of IV tPA in a dose of 0.9 
mg/kg (maximum of 90 mg), with 10% of 
the total dose given as an initial bolus and 
the remainder infused > 60 min, provided 
that treatment is initiated within 3 h of 
clearly defined symptom onset (Grade 
1A).
1.1.2.  We recommend that patients who are eli-
gible for tPA be treated as quickly as pos-
sible within the 3-h time limit (Grade 
1A).
    1.2.  For patients with acute IS of > 3 h but < 
4.5 h we suggest clinicians do not use IV 
tPA (Grade 2A). For patients with acute 
stroke onset of > 4.5 h, we recommend 
against the use of IV tPA (Grade 1A).
A more appropriate grade for Recommendation 10.2 of Italian 
guidelines should be considered a “B”. In fact there is still some 
dissent concerning the grade to be attributed to the above recom-
mendations, which cannot be influenced by the otherwise important 
results of the SITS-MOST, which was not a RCT. Clinical Evidence 
in its June 2007 release, accounting for the results of the systematic 
reviews on thrombolysis where a definite statistical heterogeneity 
was seen that make not fully reliable the results favourable to the 
treatment, continues classifying the treatment as “trade-off between 
benefit and harm”, and specifies that the treatment decreases depen-
dence among survivors but increases total mortality and fatal haem-
orrhages (Synthesis 10–1). Furthermore “The benefit from the use 
of i.v. r-tPA for acute IS beyond 3 h after onset of the symptoms is 
smaller, but present up to 4.5 h. When r-tPA is administered between 
4.5 and 6 h of stroke onset, only a statistically non-significant trend 
towards effectiveness is obtained”(Synthesis 10–2)3. The double-
blind, randomised, placebo-controlled trial ECASS III (European 
Cooperative Acute Stroke Study III) recently published on the New 
England Journal of Medicine5 provided good evidence that even 
within 4.5 hours of the onset of symptoms intravenous alteplase is 
associated with favourable clinical outcome. “The ongoing double-
bind, randomised, placebo-controlled trial, denominated IST 3, is 
estimating in a large population of patients with acute IS the risk-to-
benefit ratio of the administration of r-tPA within 6 h of onset. This 
trial also evaluates efficacy and safety in patients over 80 years of 
age” (Synthesis 10–2)3.
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Clinical Evidences Supporting Acute Stroke 
Treatments
D. Inzitari, M. Nesi, V. Palumbo, P. Nencini
Department of Neurological and Psychiatric Sciences, 
University of Florence, Florence, Italy
Stroke is the third cause of death worldwide and the first for 
long term disability. Current clinical evidence supports that stroke 
unit admission and intravenous thrombolysis with tPA are the main 
emergency treatments able to reduce the risk of post-stroke death 
and disability in about 50% of patients. Stroke unit, described as an 
hospital area with dedicated beds and trained multidisciplinary staff 
with expertise in caring for patients with cerebrovascular disease, is 
proved to be the best model for in-hospital care of any kind of stroke 
regardless of aetiology, age, sex, severity. However, in Italy only 12% 
of wards that admit stroke patients has such organization. Indeed in 
Europe less than 5% of ischemic stroke are treated with tPA because 
of the strict selection criteria and narrow temporal window within 3 
hours. An acute stroke care pathway should start from an accurate 
and fast evaluation from emergency medical service, going through 
the emergency department to the stroke unit in order to give the best 
treatment to the majority of stroke patients.
Recently the ECASS3 trial confirmed the hypothesis derived from 
meta-analysis from previous randomised control trials that intrave-
nous thrombolysis with TPA is safe and efficacious up to 4.5 hours 
from onset. The treatment efficacy is confirmed to be time dependent 
but still present after 3 hours. Indeed this implies that more patients 
are treatable but not that stroke physicians should take more time to 
treat every patient.
Intra-arterial thrombolysis in patients with severe stroke and inel-
igible to intravenous treatment is an option that seems to improve 
functional outcome despite an higher risk of intracranial bleed-
ing. Clinical evidence supporting invasive thrombolytic therapy are 
scanty and no trials proving clinical efficacy of mechanical approach 
are available at the moment.
Multimodal imaging techniques, as perfusion or diffusion MRI, 
seem to be able to detect cerebral tissue salvageable from irreversible 
ischemic damage until 9 hours from symptom onset. If ongoing trials 
will confirm this hypothesis, patients could be selected for thrombol-
ysis according to a tissue window after 3 hours from onset.
Some clinical experiences, recently described, support that carotid 
endo-arterectomy performed within few days from minor stroke or 
TIA onset seems to be quite safe and to improve functional outcome.
At the moment we have clinical evidences drawing the best care 
pathway for stroke and ongoing research seems to indicate further 
improvement; nowadays we need to translate trial results into clinical 
practice in order to improve the whole stroke care system.
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Intravenous Thrombolysis: Results of the 
Italian Sits-Most Study, ECASS III Study 
and SITS-ISTR
S. Lorenzano, A. Correnti, D. Toni
Unità di Trattamento Neurovascolare, Department of 
Neurological, University of Rome “La Sapienza, Rome, 
Italy
Intravenous (i.v.) thrombolysis with rt-PA within 3 h from 
symptom onset is the only available effective, specific reperfusion 
therapy in acute ischemic stroke. In the European Union, this treat-
ment was approved in 2002 by the European Medicine Evaluation 
Agency (EMEA) on two conditions: the setting in place of an obser-
vational safety study, the Safe Implementation of Thrombolysis in 
Stroke - Monitoring Study (SITS-MOST), to investigate whether the 
safety of i.v. alteplase given within 3 h of ischemic stroke reported 
in randomised controlled trials (RCTs) could be replicated in rou-
tine clinical practice, and the initiation of a new RCT, the European 
Cooperative Acute Stroke Study (ECASS) III, with a therapeutic 
window extended beyond 3 h. In Italy, only few centers were expert 
in thrombolysis before the SITS-MOST; globally, 586 patients were 
included. The results of the SITS-MOST study showed that in Italy, 
i.v. alteplase is safe and effective in routine clinical use compared 
with the other european centers and the RCTs, in terms of SICH 
(symptomatic intracerebral hemorrhage) as per the NINDS/Cochrane 
definition (p 0.56), mortality (p 0.75) and independence (mRS 0–2) 
(p 0.09) at 3 months, even in centers with little previous experience of 
thrombolytic therapy.
A meta-analysis of the pooled data of the main RCTs showed that 
earlier is the treatment better is the patient outcome but also that a 
significant benefit of i.v. thrombolysis persists up to 3–4.5 h from the 
symptom onset. Recently, waiting for the results of the ECASS III 
study, within the SITS-ISTR (Safe Implementation of Treatment in 
Stroke - International Stroke Thrombolysis Register) (a prospective 
internet-based register of thrombolysis in ischemic stroke, used also 
for the SITS-MOST study), it was assessed the outcome in patients 
treated intravenously within 3–4.5 h (n = 664) and compared the 
results with patients treated within 3h (n = 11865) until November 
15, 2007.
Half of patients in the 3–4.5 h cohort were treated within 15 min 
of the 3 h time limit and the difference between the median onset 
to treatment times between both cohorts was 55 min. That can be 
seen as an indication of physicians striving to stay as close to 3 h as 
possible. There were no significant differences between the 3–4.5 h 
cohort and the within 3 h cohort for any outcome measure - rate of 
SICH: 2.2% vs 1.6% (OR 1.18, 95% CI 0.89–1.55, p 0.24; adjusted 
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OR 1.32, 1.00–1.75, p 0.052); mortality: 12.7% vs 12.2% (OR 1.02, 
0.90–1.17; p 0.72; adjusted OR 1.15, 1.00–1.33 ; p 0.053); and inde-
pendence: 58.0% vs 56.3% (OR 1.04, 0.95–1.13, p 0.42; adjusted OR 
0.93, 0.84–1.03, p 0.18).
These positive results were confirmed by the ECASS III RCT that 
tested the efficacy and safety of alteplase administered between 3 and 
4.5 hours after the stroke onset. A total of 821 patients were enrolled 
in the study and randomly assigned 418 to the alteplase group and 
403 to the placebo group. The median time for the administration of 
alteplase was 3 hours 59 minutes. More patients had a favorable out-
come with alteplase than with placebo (52.4% vs 45.2%; OR 1.34; 
95% CI 1.02–1.76; p 0.04). In the global analysis, the outcome was 
also improved with alteplase as compared with placebo (OR 1.28; 
1.00–1.65; p<0.05). The incidence of intracranial hemorrhage was 
higher with alteplase than with placebo (for any intracranial hemor-
rhage, 27.0% vs 17.6%; p = 0.001; for SICH 2.4% vs 0.2%; p 0.008). 
Mortality did not differ significantly between the alteplase and pla-
cebo groups (7.7% and 8.4%, respectively; p 0.68).
These findings give to patients the chance to be treated more later 
but for medical doctors having more time does not mean we should 
be allowed to take more time.
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Stroke Services in Italy: The Research 
Project Prosit
Roberto Sterzi, Manuela Botto, Mario Pozzi, 
Daria Roccatagliata
Neurology and Stroke Unit, Niguarda Hospital, Milan, Italy
The effectiveness of organized care for hospitalised stroke patients 
was assessed in several randomised controlled trials. The results, 
combined in a Cochrane systematic review, definitively showed the 
benefit of stroke-unit care. However the implementation of stroke-
unit (SU) wards in European countries is spreading very slowly. 
The Italian National Ministry of Health has promoted a stroke-
unit research project (Research Project on Stroke services in Italy, 
PROSIT) since 2000. A last survey, in 2004, identified 785 hospital 
wards in Italy admitting at least 50 stroke/year. Only 68 were SU, 
defined as dedicated beds/geographical area with at least 1 dedicated 
full-time physician and 1 nurse. 75% of SU were in Neurological set-
ting. The most striking differences between SU and General Ward 
were related to the staffing and care organisation with higher number/
patients ratio in SU as far as physicians and nurses, speech therapists 
and social workers were concerned. A geographical gradient was evi-
dent as the SU were more frequent in northern regions than in south-
ern ones.
Starting from a survey conducted in seven Italian region, an 
observational follow-up study was conducted on a sample of 11572 
acute stroke patients hospitalised within 48 h of the onset of symp-
toms either in a stroke unit (n = 4936) or in a conventional ward 
(6636). The primary outcome was mortality or disability (Rankin 
score greater than two), assessed prospectively by independent, 
masked assessors 2 years after admission. Compared with conven-
tional-ward care, SU care was associated with a reduced probability 
of death or being disabled at the end of follow-up (odds ratio 0·81, 
95% CI 0·72–0·91; p = 0·0001). The potential benefit was significant 
across all age ranges and clinical characteristics, except for uncon-
sciousness. No specific elements of setting, organisation, or process 
of care were associated with outcome.
Some points must be considered. Recently the need to implement 
thrombolysis in clinical practice (SITS-MOST: Safe Implementation 
of Thrombolysis in Stroke: Monitoring Study) was the trigger for a 
further diffusion of the SU in Italy. However, the focus on the throm-
bolytic treatment may favour an hyperacute model of SU, in which 
monitored patients stay only 3–4 days, a model not yet validated by 
clinical trials. Indeed, the studies evaluated in the systematic review 
were conducted in comprehensive stroke units, combining acute and 
subacute care, namely early mobilization and prevention of complica-
tions of stroke.
The new hospital model, based on care intensity and now pro-
posed in Italy by Regional and National Health Authorities, may 
stand out against SU care. By this model the patient is admitted in 
ward differing for the intensity level of the care needed but not for the 
specificity of the disease. So the specifity of the stroke team and the 
dedicated beds are lost. A possible strategy to cope with this model is 
the creation of Emergency Neurologies, where to set true stroke units.
Another critical point is the relationship between the emergency 
system and the post-discharge organisation, warranting the continuity 
of care. Care pathways or integrated care strategies may offer a means 
for achieving better integration among practitioners, community-
based services, and SU care
Sterzi R, Micieli G, Candelise L, on behalf of the PROSIT col-
laborators. Assessment of regional acute stroke unit care in Italy: the 
PROSIT study. Cerebrovasc Dis 2003; 15 (suppl 1): 16–18.
Candelise L, Micieli G, Sterzi R, Morabito A, on behalf of the 
PROSIT collaborators. Stroke unit and general wards in seven italian 
regions: the PROSIT study. Neurol Sci 2005; 26: 81–94.
Candelise L, Gattinoni M, Bersano A, Micieli G, Sterzi R, 
Morabito A on the behalf of the PROSIT Study Group. Stroke-unit 
care for acute stroke patients: an observational follow-up study. 
Lancet 2007; 369: 299–305.
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Stroke: The Emergency Starts Out-of-
Hospital
A. Peris , G. Zagli, V. Anichini, S. Matano
From Anesthesia and Intensive Care Emergency DPT, 
Careggi Teaching Hospital, Florence, Italy
Stroke represents the second cause of disability and death after 
ischemic heart disease in Western Countries. The etiology of stroke 
can be mainly identify in a focal cerebral ischemia due to an acute 
arterial flow interruption (80%), whereas haemorrhage represents 
20% of events.
It is widely accepted the importance of a very early treatment 
of stroke: this concept is based on the knowledge of the dynamic 
physiopathology following the acute injury. The arterial occlusion 
produces a very low perfusion central area (“ischemic core”) sur-
rounded by a cerebral tissue (“ischemic penumbra”) with metabolic 
alteration without, in the early phase, damages. This peri-ischemic 
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area represents the goal of the early treatment, because its evolution 
in necrosis or recovery (even partial) depends on the time and the rate 
of reperfusion.
This feature of the acute cerebrovascular accident can be consid-
ered very similar, in organizational aspects, with that observed in the 
ischemic heart attack in which a very early treatment, beginning “at 
the home of the patients”, is able to increase the recovery. A correct 
diagnosis and initial treatment of stroke in pre-hospital phase, should 
therefore be considered a priority.
After a territorial first-line treatment, the correct intra-hospital 
diagnosis and assessment of ischemic or hemorrhagic injury with 
neuroimaging (CT-scan, NMR, angiography, trans-cranial ultraso-
nograpy) can lead the decision to treat with intraarterial thrombolysis 
(and other procedures) or with medical care and intravascular emboli-
zation. Beside these conventional treatment, the evaluation of patient 
from an “intensivist point of view” (based on a cerebral perfusion 
pressure optimization) , might also open “less-conventional” thera-
peutic options such as decompressive craniotomy and mild-therapeu-
tic hypothermia. This approach needs a strict collaboration between 
various specialists, and it must be considered an emergency intensive 
care regimen of treatment.
Growing evidences support that the creation of dedicated “in-
hospital pathway” for an early diagnosis/treatment of stroke produces 
a decrease in mortality and an improvement of recovery after acute 
cerebrovascular event. According with these consideration, a correct 
territorial management of stroke and the hospitalization in specialized 
center should be considered the corner stone of stroke treatment. An 
intensive-care approach might be guarantee to optimize the possibil-
ity of an early reperfusion of peri-ischemic area.
References
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Triage of Patients with Suspected Stroke
S. Grifoni, S. Vanni

Suspected stroke patients require rapid clinical evaluation to 
identify those who may benefit from timely thrombolytic adminis-
tration. The diagnosis of stroke requires focused history and physi-
cal examination as well as clinical judgment. At the moment, only 
standardized stroke scales have sufficient evidence to be used in the 
pre-hospital and very early (triage) hospital setting in patients with 
suspected stroke. In our emergency departments the CPSS is used at 
triage due to its extreme simplicity (requiring only 1–2 minutes to be 
administered), and its high reliability. Interestingly, in previous stud-
ies conducted in emergency scenarios CPSS showed a lower sensitiv-
ity than expected, missing the diagnosis in about one third of patients 
with stroke. Our data supports these findings as we observed high 
percentage of false negatives (29%) for the CPSS in our study popu-
lation. In our experience a multi-marker had an accuracy similar to 
pre-hospital standardized stroke scale (CPSS), misdiagnosing about 
one third of patients, thus discouraging their use as stand alone tests 
in triage of patients with suspected stroke. The combination of the 
two tests seems to increment diagnostic yield, encouraging further 
studies to investigate the potential clinical utility of biomarkers in tri-
age of patients with suspected stroke.
7
Integration Between Triage Physician and 
Neurologist
P. Nencini, M. Nesi
Stroke Unit, Carreggi University Hospital, Florence, Italy
Intravenous thrombolysis with tPA within 3 hours from onset 
is the principal approved drug treatment for acute ischemic stroke. 
Acute stroke must be managed as an emergency for the narrow treat-
ment time windows. Indeed the efficacy of tPA in term of recovery 
from disability is time dependent.
The recent ECASS 3 trial confirmed the hypothesis, derived from 
a previous meta-analysis of randomised control trials, that tPA could 
be efficacious up to 4.5 hours from symptoms onset, but, now the 
administration of tPA beyond 3 hours is “off label”.
An organized acute stroke care pathway with the integration of 
several personnel is essential. The implementation of a red code for 
stroke from the emergency service to the triage physician and first 
clinical evaluation of patients is necessary for a rapid assessment of 
acute stroke patients. A trained emergency department staff in car-
ing for acute cerebrovascular disease patients is necessary to improve 
screening and selection for acute phase treatment.
This model of integration between several professionals in the 
emergency department should be used even for patients with TIA in 
order to identify those patients with higher risk of stroke recurrence 
within 72 hours according to the ABCD2 score.
8
A Rapid Access to Secondary Prevention: 
“Day T.I.A. Project”
N. Marcello, A.Dallari, A.Nucera, M.L. Zedde, G. Malferrari
Neurological Dp. Arcispedale S.Maria Nuova, Reggio 
Emilia, Italy
The transient ischemic attack (TIA) is a brief episode of neuro-
logical dysfunction caused by focal brain or retinal ischemia, with 
clinical symptoms typically lasting less than one hour, and without 
evidence of acute infarction. In the literature preceding the advanced 
neuroimaging with CTscan-angiography and diffusion weighted MRI 
, the duration of the neurological deficits lasted at least 24 hours but 
in 2002 a new definition was proposed because only a deficit less 
than one hour is probably to occur without permanent brain injury 
(Albers GW et al. N. Engl J. Med. 2002;347:1713–1716). According 
to the new definition, the diagnosis of TIA needs to be confirmed by 
CT or MRI in order to exclude acute stroke. The TIA can recur show-
ing in this way the possible severity of transient episode. Often the 
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TIAs are due to embolism from large vessels pathology extra and/or 
intra cranial; also cardioembolic sources are identified as causes that, 
if they aren’t removed, can recur as TIAs or stroke. The risk of stroke 
in people affected by TIA or minor stroke is ten-fold more frequent 
than in general population in the first year from the initial episode; 
moreover during the 5 years following the transient ischaemic attack 
in non-treated patients, the risk of cerebral infarction is estimated to 
be 25%. Therefore time window for prevention is very short : the bet-
ter setting for effective procedures to prevent the stroke after TIA is 
hospitalization if :
1. the onset of TIAs is within the previous 48 hours
2. TIAs last for more than 10 minutes
3. frequent recurrence of TIAs.
However many transient neurological symptoms are not prop-
erly transient ischemic attacks: the mimic TIAs are frequently due 
to seizures, subdural haematoma, migraine. For these reasons the 
investigations about the major categories of symptom presentations 
associated to cerebrovascular risk factors have to be taken into con-
sideration to formulate the ABCD and ABCD2 (Rothwell P.M. et al., 
Lancet 2005, Jonsthon C. et al, Lancet 2007). The ABCD2 is mean-
ingful for a stroke risk during the next two and seven days follow-
ing TIA ,because the delayed arrivals into hospital of patients with 
elevated score (6–7 ABCD2) is barely effective to prevent the onset 
of a major risk. The great value of SOS TIA study (Lavallee, Lancet 
Neurol 2007) was the demonstration that early admission to locally 
structured ad hoc organization (TIA clinic) permit the reduction of 
79% of relative risk of stroke to 90 days.
On the basis of these studies we propose an organization model 
modulated according to the score and the time of TIA by creating 
the hospital pathways. This project can rely on neurologists and dedi-
cated nurses, computerized reports, CT/ MRI imaging, carotid neu-
rosonology and TCCD. The “Day TIA” is a 48 hours admission in 
Stroke Unit for patients with a score ABCD2>6; with a score of 4–5, 
patients are admitted into OBI at the ED; with a score <4 they can be 
evaluated at cerebrovascular service within seven days. At the same 
time we informed the Reggio Emilia province population about “why, 
when, where,” they could take benefit from going to “Day TIA” hos-
pital, prevention offices, ALICE group (Italian association for stroke) 
and GPs. The aim is the primary prevention by simultaneous sched-
uling neurosonologic and cardiologic examinations for people aged 
more than 60 years , with elevated blood pressure and/ or diabetes in 
order to realize the novel paradigm of prevention.
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Diagnostic and Therapeutic Pathways in 
Acute Stroke: The Point of View of 
Neuroradiologist
G.P. Giordano, D. Petacchi
SOD Neuroradiologia, Azienda Ospedaliera Universitaria 
Careggi, Florence, Italy
Diagnostic imaging modalities in evaluation of acute ictus play a 
fundamental role for a correct clinical approach. The early detection 
and knowledge by widely available and unintrusive techniques, such 
as CT and MR, of brain ischemic damage still in reversible phase 
have important therapeutic and prognostic implications, also particu-
larly in planning revascularization of intracranial arterial segments, 
by intravenous or intra-arterial thrombolytic therapy, and thromboen-
doarterectomy or stenting of epiaortic vessels.
Diagnostic-therapeutics pathway in patients with suspected stroke 
provides, first of all, to discriminate between ischemic brain injuries 
and other pathologies leading acute neurological deficit ( intracerebral 
hemorrhage, tumors, abscess, post-traumatic lesions, seizures ..), suc-
cessively to determinate the etiologic mechanism of ischemic event 
on the basis of clinical data and further aimed investigations. With 
regards to specific investigations it is possible to outline guidelines 
that, starting from clinical findings, articulate in terms of priority and 
correlation with other methodics (ultrasonography), also considering 
the accessibility to more advanced technologies.
The study of extracranial arterials and cerebral circulation, includ-
ing the research of the kind and site of endovascular lesion, represents 
a preliminary procedure to therapeutic decisions in the majority of 
ischemic events.
Noncontrast-CT is still now the imaging modality of choice for 
identifying the underlying pathology in the initial hours of acute 
stroke, because immediately exclude intracranial hemorrhage 
or tumor, and can also be used to detect early signs of an infarct ( 
iperdensity of middle cerebral artery, early parenchimal low-density, 
mass effect due to cytotoxic edema ).
At present noncontrast-MR is a complementary technique to con-
firm the diagnosis of acute ischemic event because of high sensitivity 
especially in infratentorial or lacunar lesions.
CT and MR remain the standard acute stroke imaging modality in 
the first 12–24 hours after clinical onset; in the light of recent treat-
ments by intravenous or intra-arterial trombolysis and neuroprotec-
tive agents to improve the clinical outcome, other diagnostic tools 
are needed that quickly (within 3–6 hours) shows not only lesion size 
but also vessel occlusion and that provides information about the col-
lateral circulation, tissue at risk and salvageable brain ( ischemic pen-
umbra ).
In the evaluation of epiaortic and intracranial vessels ultraso-
nography is actually employed, in association with Angio-CT and 
Angio-RM, also if this methodic present some limits to assess the 
degree of stenosis and characterize the pathologic arterial walls.
Dynamic contrast-enhanced CT and MR imaging techniques such 
as the Perfusion-Weighted CT and Perfusion-Weighted MR imaging, 
associated with Diffusion-Weighted MR, arouse great interest help-
ing predict clinical outcome at very early time points and allowing 
the identification of optimal candidates for therapeutic interventions, 
including thrombolysis ( ie, those patients with a sizeable volume of 
potentially salvageable tissue at risk ).
Cerebral angiography, non risks exempt and performing only in 
qualified centers, is not recommended in the iperacute phase of stroke 
with the exception of selected cases for revascularizing treatments ( 
i.a. thrombolysis, stenting ).
Digital angiography, besides confirming site and nature of the 
vascular occlusion, gives information about existence and goodness 
of collateral circulation, involvement of deep territories, wideness 
of avascular area by parenchimography, and about the endovascular 
accessibility for thromboembolic therapy. With regard to this inter-
ventional procedure is of primary importance the site of embolic 
occlusion and it is essential to observe “therapeutic window” of 4–6 
hours for carotid districts, but wider for vertebro-basilar occlusions.
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Is Vascular Diagnosis only a Luxury Option 
in Acute Ischemic Stroke?
S. Castellani*, D. Inzitari**, I. Tanini*, V. Palumbo**, 
P. Nencini** F. D’Abate*, G. Pracucci** G.F. Gensini*
Institute of Internal Medicine and Cardiology, Department 
of Critical Care Medicine and Surgery, University of 
Florence.* Department of Neurology. University of 
Florence** , Florence, Italy
Different trials have investigated the benefit of intravenous 
thrombolysis in acute stroke but only few prospective studies have 
evaluated the recanalization rate after therapy and the rate of hemor-
rhagic complications according to the initial vascular status. Despite 
the lack of prospective data the knowledge of the baseline vascular 
status is fundamental for prognostic purposes and its assessment may 
provide very valuable information to plan the appropriate therapeutic 
strategy. Indeed retrospective analyses have clearly demonstrated that 
the proximal extension of arterial occlusion is correlated with a tech-
nical success of lysis, neurologic recovery and risk of intracerebral 
hemorrhage. In addition it has been reported that despite comparable 
age and NIHSS scores before IV tPA, the rate of recanalization and 
clinical outcome are sharply different and definitely better in patients 
with MCA obstruction compared with those affected by ICA occlu-
sions. Patients with proximal carotid occlusion may achieve early 
recanalization only after combined IV/intra-arterial or mechanical 
thrombolysis. To assess the effects of the vascular assessment in the 
clinical management of the acute stroke patients admitted to our hos-
pital, we have retrospectively analyzed the results of cerebrovascular 
ultrasound (US) examinations performed between November 2005 
and the end of March 2008 and we have matched the results with 
neuroradiological and clinical data. 551 patients were evaluated by 
the stroke team physicians for a suspect cerebral ischemic attack. 
330/551 underwent a cerebrovascular US examination either soon 
after admission or within 48 hour after symptoms onset (59.8%). Only 
247 patients were transferred to the stroke unit; 178/247 did have an 
acute cerebral ischemia (TIA or stroke). The results of brain CT and 
vascular ultrasound examination and exhaustive informations on the 
clinical course (up to one week of hospitalization) could be retrieved 
exclusively from the 178 stroke unit patients. 83 of the 330 (25%) 
patients with suspect cerebral ischemia were studied during the acute 
phase, soon after admission in the emergency room (ER). US exami-
nation was limited to neck arteries in 43; both extra- and intracranial 
vessels tests were performed in the remaining 40 patients. 3/40 had 
a significant MCA stenosis; 4 showed an M1 MCA occlusion. 112 
patients were treated with fibrinolysis: tPA was administered intrave-
nously to 63 patients, and intra-arterially to the remaining 49 patients. 
A bridging strategy was adopted in 4. US examination was performed 
in 33 patients receiving I.V. tPA (19 extracranial; 14 extra- and intra-
cranial evaluation). US examination was performed in 9 of the 49 
patients intra-arterially treated (6 extracranial; 3 extra- and intracra-
nial evaluation); in all patients the ultrasound evaluation was readily 
feasible within 3 hours after symptoms onset. 51% of the patients 
receiving systemic rTPA were studied by carotid ultrasound; 37.8% 
were studied also with TCCD and TCD. Continuous TCD monitoring 
was performed during tPA infusion in 4 patients and provided direct 
evidence of progressive recanalization in two; lack of effects in the 
remaining two. The recanalization anticipated by more than one hour 
the functional neurological recovery in one of the patients success-
fully treated. Significant (70–95%) carotid stenosis was diagnosed 
by ultrasound in 10.8% of the patients investigated during the acute 
phase and were subsequently treated; a total carotid occlusion was 
found in 16.9%. Carotid dissections were present in 6.1% of cases. 
During the acute phase 12 patients underwent an angioCT, 7 angi-
oMR, 19 an angiography. The results of the neuroradiological and 
ultrasound examinations were similar in all patients examined by 
both techniques. The detection of a pathological finding at vascular 
Doppler examination was significantly correlated with clinical wors-
ening, both at ER admittance and within the stroke unit (p<0.05 and 
p<0.01 respectively). Statistically speaking present data do not allow 
to jump to absolute conclusions since the sample analyzed is not fully 
representative of the whole population with acute stroke admitted to 
our hospital. Nonetheless the results clearly indicate that the eligibil-
ity to fibrinolysis is not the only issue to face in the presence of an 
acute stroke patient. In fact in our study the assessment of the vascu-
lar status prior to fibrinolysis has allowed to characterize some sub-
groups in which a different therapeutical strategy was indicated like 
for example a surgical or procedural correction in the case of carotid 
stenosis or heparin infusion in carotid dissections. The early neuroso-
nological findings proved to be very effective to define patient prog-
nosis. This holds true not only for main stem M1 MCA occlusions but 
especially in the presence of T occlusions of the internal carotid arter-
ies where any thrombolytic treatment can hardly succeed and is too 
often associated with hemorrhagic complications and clinical deterio-
ration. Unfortunately none of the methods that are commonly used 
to establish the eligibility to fibrinolysis of an acute stroke patient 
can reliably assess the site and extension of an occlusion. The sys-
tematic adoption of US vascular evaluation can achieve the vascular 
diagnosis at ER admittance and since it can be repeated according 
to the very common clinical fluctuations, it is the only method that 
can instantly provide an anatomic correlate to clinical symptoms and 
an accurate bedside monitoring of cerebral hemodynamics. From an 
organizational point of view US evaluation may be prospectively 
considered a mandatory choice rather than a luxury option.
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Diabetes and Ischemic Stroke
G. Licata, A. Tuttolomondo
Dipartimento Biomedico di Medicina Interna e 
Specialistica, Università degli Studi di Palermo, Italy
In many (1–12) but not all (13–14) epidemiological studies, type 
2 diabetes mellitus (DM) has been reported as an important risk factor 
for ischemic stroke with relative risks (RRs) that have varied widely, 
from 1.3 to 4.9 (1–11). The disparate RRs may be explained in part 
by differences in populations, definitions of diabetes, types of stroke 
studied, and analytical methods. Further, only a few small studies 
have examined the risk of stroke in patients with type 1 diabetes 
(8,9). This relationship remained a long time partially unsettled until 
Janghorbani et al reported cerebrovascular complication distribution 
pattern in subjects with type 1 diabetes showing that the RR of isch-
emic stroke was increased sixfold in type 1 diabetes and twofold (2.3 
[2.0–2.6]) in type 2 diabetes. (15)
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The increased risk of stroke has been linked to the pathophysi-
ological changes seen in the cerebral microvessels (small vessel dis-
ease or SVD) of individuals with type 2 diabetes mellitus owing to the 
fact that DM is responsible of a tipical microangiopathy of cerebral 
vessels that differs in comparison with non-diabetic ones. Indeed, 
while pathological studies indicate that the diabetic angiopathy is dif-
ferent from the atherosclerotic angiopathy on the basis of pathologi-
cal and autopsy reports (16,17), epidemiological data do not find a 
unique clinical and prognostic profile for ischemic stroke in diabetics. 
For example, whereas Lithner et al (19) and Toni et al. (20) reported 
that ischemic stroke severity, in both diabetics and non-diabetics, 
was similar, Kiers et al. (21) found that diabetic patients had more 
severe strokes. Moreover in a retrospective study, Pulsinelli et al. (22) 
reported that the neurological outcome of stroke was poorer in diabet-
ics, whereas Toni et al (20). found a comparable functional outcome 
for both diabetics and non-diabetics patients.
Small vessel disease of deep perforating arterioles plays a crucial 
role in ischemic stroke pathogenesis in diabetic subjects, although the 
higher cerebrovascular risk is also related to the additional risk fac-
tors and the characteristic atherogenic diabetic profile and significant 
appears the pathogenetic role of acute hyperglycemia as a direct neu-
ronal damage mediator and negative prognostic marker.
More recently two studies analyzed the differences regarding clin-
ical features of stroke in diabetic and non-diabetic subjects. Megherbi 
et al. (22) reported that diabetic patients compared with those without 
diabetes were more likely to have limb weakness, dysarthria with a 
handicap (Rankin Scale) and significantly higher disability (Barthel 
Index) grade, while Karapanayotides et al. (23) reported that diabetic 
stroke patients are not associated with a poor functional outcome. 
Furthermore our group (24) reported that diabetes, hypertension, 
and a history of transient ischemic attack were more frequent among 
patients with lacunar stroke and that mean SSS score on admission 
was significantly lower in patients with lacunar stroke in comparison 
with patients with LAAS and CEI subtypes. In a subsequent study 
(25) we compared 102 diabetics and 204 non-diabetic subjects with 
acute ischemic stroke, matched by sex and age confirming that dia-
betes was associated with lacunar ischemic stroke subtype, with a 
record of hypertension, and with a better SSS score at admission and 
that association of diabetes with lacunar stroke remained significant 
even after adjustment for hypertension or other stroke subtypes . Our 
group (26) also recently reported that lacunar stroke (more prevalent 
in diabetes) has a lower immuno-inflammatory activation of the acute 
phase compared to other subtypes of stroke, so partially explaining 
clinical and prognostic difference of this subtype and furtherly con-
tributing to characterize the peculiar profile of ischemic stroke in dia-
betic subjects .
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Atherosclerosis and Cardiovascular Events
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Cardiovascular diseases remain today the first cause of death 
in the world. Understandably, the knowledge and the prevention of 
cardiovascular risk factor have attracted particular attention. Beyond 
“traditional” risk factors such as age, gender, family history of CV 
disease, hypertension, hyperlipidemia, smoke and diabetes, very 
important as well are the “emerging” marker of risk such as carotid 
Intima-Media Thickness (IMT).
IMT is a not invasive, low cost, no radiation, cost-effective and 
highly reproducible procedure to screen for atherosclerosis. Carotid 
Artery IMT is measured with laser Doppler velocimetry.
The Doppler mode permits the visualization of vessels and an 
evaluation of flow disturbances. It measures the IMT and the size 
and number of atheromatous plaques. IMT is defined as the distance 
between the media-adventitia interface and the intima-media inter-
face. IMT is measured at five locations on each side and, in particular, 
it is measured at internal carotid artery (ICA) about 1 cm distal from 
the flow divider, at bifurcation enlargement (BIF) and at proximal, 
middle and distal segment of the common carotid artery (CCA) is 
measured.
Carotid IMT has been shown to be an independent marker of 
multifocal atherosclerosis. Now it is established that IMT is an inde-
pendent predictor for cardiovascular events: increase in IMT of the 
carotid artery, as measured non-invasively by ultrasonography, is 
directly associated with an increased risk of myocardial infarction in 
adults without a history of cardiovascular disease.
Cardiovascular RF are associated with an impaired endothelial 
function and an increased IMT, and the presence of carotid IMT is 
significantly related with endothelial dysfunction (p < 0.01). In a 
study of our group impaired flow mediated vasodilatation (FMD) and 
values of carotid IMT have been found to be higher among patients 
with cardiovascular risk factors than among patients without RF (1). 
Clinical studies have shown an important relation between smoking 
and IMT (2). In fact, IMT increases with age and hypertension, hyper-
lipidemia and non-insulin-dependent diabetes mellitus are related to 
a greater IMT (3).
Interestingly, there is a good correlation between Framingham 
risk score and IMT (4).
Another study examined the relation between IMT and a number 
of arterial beds with significant (> 50%) stenoses, including coronary, 
supra-aortic, renal and iliac/femoral arteries. It showed that IMT was 
significantly correlated to the number of coronary vessels with ste-
noses (p < 0.001). So, IMT has been shown to be an independent 
predictor of significant multifocal atherosclerosis, showing high sen-
sitivity and specificity for indicating more advanced atherosclerotic 
involvement (5, 6).
Observational studies have shown a relationship between carotid 
intima-media thickness (IMT) and coronary artery disease (CAD); 
for example, studies such as the “Prospective Finnish Study”, 
“Atherosclerotic Risk in Communities (ARIC)”, “Rotterdam Study” 
and “Cardiovascular Health Study” showed a significant relationship 
between IMT and cardiovascular risk and provided evidence that 
carotid IMT is related to future cardiovascular events (7–11).
In a study of our group, performed in asymptomatic high risk sub-
jects followed for 5 years, a significant increase of fatal and non fatal 
cardiovascular events in those subjects that at baseline present IMT or 
asymptomatic carotid plaques in comparison to subjects with normal 
carotid arteries at baseline was shown (12).
In conclusion Carotid ultrasound can add information beyond 
assessment of traditional risk factors which may help to make deci-
sions about the necessity to institute medical treatment for primary 
intervention.
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Genetics and Stroke
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Hereditary factors play an important role in stroke and cerebro-
vascular diseases in general and this effect may be commonly appre-
ciated in the daily practice. Studies performed on animal models and 
epidemiological investigations on twins have well demonstrated the 
role of hereditary factors in the etiopathogenesis of stroke. In this 
regard, the search of a candidate gene as cause of stroke has been 
long-lasting and intensive but until now disappointing except for a 
few specific but relatively rare diseases. Among monogenic cere-
brovascular diseases the following are listed: CADASIL (Cerebral 
Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy) and Anderson-Fabry disease both small vessel 
diseases, HCHWA-D and HCHWA-I (hereditary cerebral hemorrhage 
with amyloidosis respectively of Dutch and Icelandic type) causing 
hemorrhagic stroke and dementia, and Marfan syndrome associ-
ated with arterial dissection, in which the involved genes have been 
definitively identified. CADASIL is caused by mutations on Notch3 
gene, Anderson-Fabry disease by a defect in α-galactosidase A gene, 
HCHWA-D and HCHWA-I respectively by mutations on AβPP and 
cystatin C gene, while Marfan syndrome is due to mutations in the 
fibrillin-1 gene or in the transforming growth factor-β receptor2 gene. 
In particular, CADASIL has an autosomal dominant pattern of inheri-
tance and is characterized by recurrent strokes, migraine, often with 
aura, psychiatric disturbances and cognitive decline. CADASIL is 
also a useful model for understanding the relationship between small 
vessel disease and cognitive impairment.
A recent meta-analysis by Casas and co-workers found that there 
is a genetic component also to sporadic stroke. No single gene with 
major effect was identified; rather, common variants in several genes, 
each exerting a modest effect, likely contribute to the risk of stroke. 
The failure of the candidate gene approach has a number of possible 
explanations and the first is that stroke consists of many different sub-
types, each of whom may have a different genetic profile. Finally, it 
should be considered that stroke is a multifactorial disease and the 
effect of genetic factors is strictly related with that of the environmen-
tal and common cardiovascular risk factors.
14
Bone Marrow-Derived Progenitor Cells in 
Cadasil Patients: Association with the 
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Introduction: Cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) is a rare 
hereditary small vessel disease with many cerebral manifestations 
such as recurrent stroke, migraineous headache, mood disturbances, 
cognitive decline, and epilepsy. To date, the pathogenetic mechanism 
of CADASIL is not fully understood and recently an involvement 
of the endothelium dysfunction has been hypothesised. A number 
of studies have shown a participation of endothelial progenitor cells 
(EPCs) and haematopoietic progenitor cells (HPCs) in the mainte-
nance of endothelium health and in the neovascularization of brain 
artery ischemic syndrome, suggesting a role for both in cerebrovascu-
lar disease. However no data are available about EPCs and HPCs in 
CADASIL patients.
Aim: To analyze the number of EPCs and HPCs in a populations 
of CADASIL patients and in a population of healthy subjects in order 
to clarify the possible relationship with the pathology.
Methods: In 27 CADASIL patients [11M/16F; median age 51.3 
(29–81) years] and in 27 non-CADASIL healthy subjects [12M/15F; 
median age 50.5 (29–88) years] EPCs and HPCs were evaluated with 
the use of flow cytometry. Were defined as EPCs cells positive for 
CD34+KDR+, CD133+KDR+ and CD34+CD133+KDR+ and HPCs 
cells CD45dim and positive for CD34+, CD133+ and CD34+/CD133+.
Results: Circulating EPCs levels were significantly reduced 
(p = 0.003) in CADASIL patients with respect to healthy subjects, 
while circulating HPCs levels were similar between patients and 
controls. In a logistic regression analysis, after adjustment for age, 
gender and traditional cardiovascular risk factors, an increased risk 
of CADASIL for patients with low EPCs levels was demonstrated 
[OR (95%IC): CD34/KDR 6.79 (1.19–38.6) p = 0.031; CD133/
KDR 6.84(1.08–43.8) p = 0.040; CD34/CD133/KDR 9.4(1.35–65.8) 
p = 0.023]. By dividing CADASIL patients into two groups, (group 
A comprised patients with a “severe clinical picture” with a previous 
documented stroke and/or dementia and group B identified patients 
with a “mild clinical picture” without stroke and dementia) group A 
showed a significant lower number of HPCs than group B. In a mul-
tivariate model, adjusted for age and hypertension, higher number of 
HPCs remained significantly associated with the mild clinical pic-
ture [OR(95%IC): CD34+: 0.25 (0.07–0.90), p<0.05; CD133+ 0.21 
(0.05–0.83) p<0.05; CD34+/CD133+ 0.25(0.07–0.90) p<0.05]. In 
addition, significant associations (p<0.05) were observed between the 
numbers of all the three types of HPCs and cognitive, functional and 
motor tests, such as Mini Mental State Examination, Stroop III test, 
Delayed word recall, Verbal fluency and Short Physical Performance 
Battery.
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Conclusions: In the present study we investigated, for the first 
time, peripheral blood EPCs and HPCs levels in CADASIL patients 
and in a comparable group of healthy subjects, documenting an 
involvement of EPCs and HPCs in the pathogenesis of CADASIL 
and in relation with a phenotypic expressivity.
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Atrial Fibrillation and Stroke: Prevalence, 
Prevention and Secondary Prophylaxis
L. Padeletti A. Paoletti Perini
Istituto di Clinica medica e Cardiologia,Università di 
Firenze, florence, Italy
Atrial Fibrillation (AF) is the most common arrhythmia in clini-
cal practice, with incidence and prevalence increasing with age, up 
to more than 10% over the age of 80. The absolute risk to develop 
AF during the whole life is about 25% at any age and is higher for 
men than for women. AF is associated with cardiac and not-cardiac 
comorbidities, and has a tremendous impact on clinical status, as it 
doubles the overall risk of death and increases 4–5 fold the rate of 
stroke, being responsible for more than 20% of all of them. To pre-
vent the occurrence of embolic stroke, anticoagulation has proved to 
be effective both in primary and in secondary prevention. CHADS2 
score identifies the best therapeutic strategy for each patient.
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Nurses Care and Clinical Monitoring of 
Acute Stroke Patients
A. Ferrara
Infermiera, Stroke Unit e Neurologia, AOU Careggi, 
Firenze, Italy
The efficacy of stroke units has been extensively examined 
showing that stroke patients who receive organised inpatient care in 
a stroke unit are more likely to be alive, independent, and living at 
home one year after the stroke(1).
Experienced and multidisciplinary team,continuing stroke 
education,early rehabilitation therapy and the active involvement of 
the family are at the basis of stroke unit organization.
Nursing plays a crucial role in stroke treatment, prevention, and 
education(2).
The primary tasks for nurses staff are
– monitoring and evaluation of vital parameters
– neurological evaluation with acute stroke assessment scale
– intensive monitoring of thrombolysed patients
– evaluation of the nutritional status and “nutritional risk”
– diagnosis and management of disphagia
– diuresis monitoring and management of urinary retention
– evaluation ef stipsis and fecal incontinence
– early mobilization and good bed positioning
– prevention and treatment of pressure ulcers
– falling prevention
– communication with patients affected by speech disturbance
– deep venous thrombosis prevention
– information
The Scandinavian Stroke Scale is an acute stroke assessment scale 
used for the evaluation and for the clinical monitoring in stroke acute 
phase and based on scored assessment of: level of consciousness, eye 
movement, arm motor power, hand motor power, leg motor power, 
orientation, speech, facial palsy and gait. It has the advantage to be 
simple and fast (about 5 minutes to be completed) (2).
All the stroke patients should be screened for the nutritional 
status. Dysphagia is a common complication following stroke and 
affects up to 80% of stroke victims.Because the complications of dys-
phagia are great (aspiration leading to chest infection, malnutrition, 
increased length of hospital stay, remission to the hospital and mortal-
ity), it is important to perform an early evaluation of dysphagia with 
a standardized scale and determine if alternate means of feeding are 
required. Diet modification and fluid consistency should be evaluated 
considering the severity and the presenting signs and symptoms of 
dysphagia(2).
Urinary infection is the most frequent infective complication 
of acute stroke patient. The incontinent patients should be care-
fully examined and the urethral catheter placed only if behavioural 
changes, nursing care, special clothes and special device to collect 
urine have not been successful.
Pressure ulcers are a frequent complication in stroke patients and 
they are associated with an higher risk of mortality and bad func-
tional outcome.Risk factors are diabetes, obesity and malnutrition. 
Stroke patient should be regulary moved (every 1 to 4 hours). This 
reduces the chance of getting pressure ulcers (bed sores) . There are 
also devices that can help to relieve pressure like the air mattresses, It 
is also very important to keep the skin clean and dry, especially if the 
patient may be incontinent.
It is important to identify patients at risk of falling and to make the 
hospital setting adequate to disabling people.
The shoulder is really vulnerable to capsular stretching due to 
gravity effect or to incaute mobilization. This is the reason why it is 
necessary to prevent thraumas by a correct bed and wheelchair posi-
tioning.(3).
Deep venous thrombosys is a frequent complication of stroke 
patients with impairment in motor function. Compression stockings 
should be routinely used after a careful examination of peripheral cir-
culation, sensory function and of the presence of skin lesions(2,3).
The nurses should encourage the communication with patients 
even if affected by speech disturbance. It is also important to estab-
lish a good relationship with the family and to inform them even by 
written informative brochure. It is important to identify the caregiver 
that should be informed about his important role to make easier the 
transition of the patient from hospital to home, to encourage as much 
independence as possible even supporting the participation in leisure 
activities.(2,3).
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Early Rehabilitation for Acute Stroke 
Patients
G. Carlucci
Department of Neurological and Psychiatric Sciences, 
University of Florence, Florence, Italy
Strong evidence show that organised care provided by dedicated 
staff (stroke unit care) is not only cost effective, but highly effective 
in preventing death and long term disability in stroke patients com-
pared to care provided on general medical wards alone. Stroke unit 
care is typically provided by a coordinated multidisciplinary team 
operating within a discrete ward, which can provide a substantial 
period of rehabilitation when required. Favourable outcomes appear 
to be independent of patient age, sex, or stroke severity.
Fundamental aspects of effective stroke unit care include:
•  accurate and rapid diagnostic workout
•  evidence based treatment
• close monitoring of neurological status and physiological 
parameters
• prevention of the complications of stroke and recurrent stroke
• early institution of multidisciplinary rehabilitation focused on 
achieving functional goals and early development of an individu-
alised discharge plan.
Scientific evidence and specific expertise in stroke care recom-
mend experienced, dedicated, multidisciplinary team as a key prin-
ciple in the optimal management of stroke patients. The team should 
comprise non-medical (nurses, physiotherapists, speech therapists, 
occupational therapists, neuropsychologists, social workers) as well 
as medical professionals.
The main features of effective stroke rehabilitation include a func-
tional approach targeted at specific activities e.g. walking, activities 
of daily living, frequent and intense practice, and commencement in 
the first days or weeks after stroke.
In particular a retrospective analysis of patients who received 
stroke unit rather than general medical ward care, showed that very 
early rehabilitation, with an emphasis on mobilization, is one of the 
greatest contributors to better outcome. It is well accepted that stroke 
rehabilitation should start as early as possible for the best achiev-
able recovery. Exactly how early rehabilitation should begin is con-
troversial. Early mobilization (getting up out of bed within 24 h of 
stroke onset) is a well-established feature of acute stroke care in many 
advanced hospital settings, nevertheless widely diffused clinical prac-
tice still enforce bed rest for the first few days or foster long periods 
of bed rest after stroke. Preliminary data from a phase II, multicen-
tre, randomised controlled trial, A Very Early Rehabilitation Trial for 
Stroke (AVERT), provided evidence that getting stroke patients out 
of bed and engaging in early intensive exercise therapy within 24 
hours of symptom onset is a safe method of rehabilitation — even 
among individuals who have been treated with tissue plasminogen 
activator (tPA). Furthermore it showed also that very early mobiliza-
tion is likely to be cost-effective. It is potentially deliverable to 85% 
of the acute stroke population and may help reduce acute stroke com-
plications such as deep vein thrombosis, skin breakdown, contracture 
formation, constipation, and pneumonia.
In the early phase of acute stroke, rehabilitation is not exclusively 
focused on secondary and tertiary prevention but also on enhance-
ment of neurological recovery, by early therapy initiation, starting 
with range-of-motion exercises and changes of bed position and con-
tinuing with a progressive increase in the level of activity as soon 
as medically tolerated. The rehabilitation project and the related pro-
grammes are generally designed in few days after a stroke and they 
undergo a regular audit and reassessment. Functional assessment of 
stroke patients should therefore be based on validated standardized 
assessment tools to tailor a comprehensive treatment plan.
Information and education of the patient and family is fundamen-
tal for increases the probability of informed decision making social 
adjustment, and maintenance of rehabilitation gains.
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Assessment of the Psychological and 
Emotional Burden on Patients and 
Caregivers
L. Bartolini, C. Nunziati

It has become increasingly clear from clinical practice with stroke 
patients and recent publications that attention must be given to the 
role of the caregiver. A sudden pathological event such as a stroke 
implies not only direct consequences for the patient but also indirect 
consequences for the family members and, in particular, the person 
who assumes responsibility for looking after the patient (the care-
giver). The long-term fulfilment of this role may lead to disruption 
of the individual’s personal psychological equilibrium, increasing the 
probability of the insurgence of depression.
Until now, the literature has only dealt with “ post-stroke depres-
sion” in relation to the patient, without taking into consideration the 
likelihood of depression arising in the caregiver who has to give 
moral and physical support to the patient on a daily basis.
Various studies have brought to light certain characteristics in the 
patient and the caregiver whose interaction could influence the onset 
of symptoms of depression. For instance, if the caregiver is a partner 
and, therefore, more deeply emotionally involved with the patient, 
if he/she is over 65, or uses coping strategies of a passive kind, they 
would seem to have a greater tendency to become depressed than 
others. Among the characteristics affecting the patient, the most rel-
evant, apart from being over 65, appear to be the seriousness of the 
stroke (assessed through NIH), the entity of the disability (indicated 
by MRS), the neuro-psychological symptomatology associated with 
the event (evaluated through STMS and MMSE) and previous strokes 
or periods of depression. (Berg et al., 2005; Cameron et al., 2006; 
Paolucci et al., by DESTRO Study Group 2006).
Our study was inspired by the need to define the precise role of 
the variables and assess their level of contribution to the manifesta-
tion of depression in the caregiver.
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Patients from the Stroke Unit of the Careggi University Hospital 
in Florence were asked to participate and a protocol was created 
designed to assess the presence of the variables and their interplay 
with the patient’s and the caregiver’s backgrounds.
Even if this study is still underway and the results are, therefore, 
not yet definitive, it has clearly shown the importance of applying the 
protocol in the sub-acute phase. Evidence has also emerged that the 
employment of active coping strategies on the part of the caregiver 
and his/her full involvement in the care-giving, favour adaptability 
and help prevent the insurgence of depression in the caregiver him/
herself.
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Barcelona Stroke Unit
C.A. Molina
Neurovascular Unit, Hospital Vall d´Hebron, Barcelona, 
Spain
Continuous and comprehensive clinical, hemodynamic and imag-
ing monitoring of stroke patients has demonstrated to improve not 
only patients selection for specific treatments but also clinical out-
come. Early detection of clinical deterioration by means of serial 
NIHSS score assessment, blood pressure drop or marked BP vari-
ability by continuous BP monitoring and vascular status by carotid 
US and TCD monitoring is crucial for isquemic tissue and clinical a 
outcome. Specific monitoring protocol according to stroke subtype 
may optimize the efficiency of care in an acute Stroke Unit.
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Stroke Unit Organization in Lombardia, 
Northern Italy
Giuseppe Micieli, Giancarlo Fontana°
IRCCS Istituto Clinico Humanitas, Rozzano, °Assesorato 
Sanità, Regione Lombardia, Italy
Despite a different approach to the problem of stroke unit (SU) 
organization in the different italian regions, a quite similar concept 
may be considered as a guideline in the different realities. It derives 
from the study planned and realized in Italy by the PROSIT study 
group, coordinated by researchers from Lombardia after preliminary 
results obtained in 7 italian regions. Data obtained by that survey 
demonstrated that also in our Country, SU showed a clear beneficial 
effect on death and disability in acute stroke patients and this effect 
was mainly due to structural and functional organization of this units 
as well as from the hospital setting.
In the Lombardia region the concept of SU as Cerebrovascular 
Unit (UCV) was developed since 2002 in the regional heath program 
which defined as SU (or UCV) semi-intensive, neurological unit 
similar to the coronary unit. In the following health plans the idea of 
SU was further developed and some of the main concept concerning 
their organization have been described in a programmatic document 
very recently (September, 18) issued. Together with a distinction of 
SU (UCV) into three different levels of organization (first level: dedi-
cated personnel and beds but no authorization to thrombolytic treat-
ment; second level: the same plus thrombolytic treatment authorized; 
third level: the same of the second one plus neurosurgery, neuroradi-
ology, endovascular treatment and intraarterial thrombolisis, vascular 
surgery) this plan describe the exact pathway from home to hospital 
(and also after hospitalization) of a patients with stroke, in particular 
when the critical event occurs within 120’. In this case a quick acti-
vation of 118 (emergency number for our Country) is followed by 
the administration of Cincinnati pre-hospital stroke scale by the 118 
personnel which is authorized to treat stroke as a high level emer-
gency (red code) and to bring patients to the closer hospital provided 
by a SU (UCV). At the arrival to hospital, a very defined path, well 
characterized in terms of exams and time to spent in their realization, 
has been described by the regional document in order to guarantee a 
quick definition of diagnostic and therapeutic approach to this pathol-
ogy in every case. Of course, this path describe the definitely access 
to SU(UCV) as soon as possible, also allowing to threat patients in 
emergency room if it could be the case (for example in the case of 
temporary occupied SU beds or when time is vey limited for throm-
bolytic treatment). A very interesting hypothesis of work is repre-
sented by the extension of the emergency service protocol of Milano 
city to the remaining services of the entire region. In this case each 
emergency service could have every time the occupancy of beds in 
each SU in the region territory, so that patients is transported directly 
to the hospital with non-occupied beds in SU.
Another interesting and organized approach to the treatment of 
acute stroke in our region is represented by the realization of the 
regional stroke unit network, called Stroke Unit Network (SUN) 
Lombardia. Thirty-seven units of the region agreed to participate into 
the project which is characterized by the use of a common data base 
for the monitoring of the process of care realized in each SU, as well 
as to verify the application of Italian stroke guidelines (SPREAD) and 
their effects of the outcome of single patients.
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The realization of this network represents the basic element for 
the creation of a pathology network dedicated to cerebrovascular 
diseases, similarly to that realized for tumors or haemathological 
diseases. The aim of this projects is, at the moment, to facilitate the 
coordination of centers with different experiences and background as 
well as to promote the adoption of common protocols of diagnosis 
and treatment of acute stroke and its follow up. An hospital registry 
has been realized started last year and now collecting more than 6 
thousand records of patients treated in 29 SU (UCV) of our Region. 
The participation to this project and registry of different actors (emer-
gency service, rehabilitation, neurosurgery, vascular surgery, general 
practitioners) which are interested in the treatment of stroke patients, 
together with the implementation of telemedicine models able to sim-
plify the correct distribution of patients on the basis of their severity 
and needs represents the target of this organization which we have 
to develop in the future in order to better assist patients with stroke.
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Multidisciplinary Italian Guidelines. 
A Statement of Diagnosis and Treatment 
of Carotid Pathology
G. Lanza
Vascular Surgery Department, Multimedica IRCCS, 
Castellanza, Italy
Relying on the most important trials in literature and on the mul-
tidisciplinary Italian Guidelines for Stroke – SPREAD (www.spread.
it), in order to examine the latest indications for diagnosis and ther-
apy in case of carotid atherosclerotic lesion, we are distinguishing 
patients as for symptomatic (maximum interval of three months from 
symptom) and asymptomatic for cerebral ischemia, and applying to 
the NASCET and ECST evaluation criteria for carotid stenosis.
Echo-Doppler examination of supra-aortic vessels is recom-
mended in patients with TIA or recent stroke for the pathophysiologic 
work-up, and in asymptomatic subjects with a high carotid stenosis 
prevalence.
Carotid endarterectomy (CE) is recommended in case of symp-
tomatic carotid stenosis (SCS) more than 70% (NASCET method), 
but CE is not recommended for SCS less than 50%. In patients with 
SCS between 50% and 70% CE is indicated mainly in case of recent 
ischemia, non ocular symptoms, ulcerated plaque, old age, male sex 
and presence of diabetes.
Surgical indications are relative in case of asymptomatic patients 
with carotid stenosis more than 60% (NASCET method), under the 
assumption that the perioperative major complications are much less 
than 3% and with respect to life perspectives of patient.
As pre-operative examination for the diagnosis echo-doppler 
examination can be assumed to be satisfactory enough, if validated by 
comparison with angiographies or surgical findings. Complementary 
RMI angiography is indicated when multiple lesions, proximal or 
distal stenosis at carotid bifurcation and vascular malformations are 
suspected.
The use of traditional angiography is indicated either in presence 
of conflict between echo-doppler and RMI angiography, or when 
RMI is contraindicated or not at disposal.
Deciding the timing of CE in symptomatic patients, in case of TIA 
or minor stroke and a negative or small lesions on cerebral CT scan 
the surgical approach is recommended as soon as possible, but in case 
of large CT lesions the early surgical procedure is not recommended, 
independently of the neurological impairment.
Regarding to cerebral protection in case of surgical procedures 
un-randomized studies suggest a potential benefit from locoregional 
anaesthesia in comparison to general anaesthesia, which anyway 
requires a well controlled monitoring with EEG or Somatosensory 
Evoked Potentials. Endoluminal temporary shunt is indicated not for 
routine, but in case of cerebral intolerance to the clamping.
At present percutaneous transluminal angioplasty and primary 
stenting of carotid stenosis are not considered safe as CE and long 
term results are necessary, together with randomised controlled trials 
of comparisons, in order to assess an evaluation about these innova-
tive endovascular procedures. At the very moment, they are suggested 
in selective cases where advantages over CE are very evident: reste-
nosis, stenosis with regular surface and homogeneous to echographic 
findings, stenosis not of the carotid bifurcation or post-radiotherapy.
Antiplatelet therapy is recommended before and after surgical 
intervention and the surgical correction of restenosis is recommended 
if severe and clinically symptomatic.
In presence of emergency, e.g. in case of acute stroke or stroke in 
evolution, studies in literature or experiences in centers of excellence 
seem to show benefits from the surgical therapy in comparison to the 
medical one. The indications to surgical procedures in emergency 
(within the first hours) are severe carotid stenosis or thrombosis, the 
lack of haemorragic cerebral lesions through TC scanning and the 
absence of severe cerebral compromissions such as coma.
Intra-arterial thrombolysis can be associated to CE in case of 
thrombosis in the intracranial internal carotid artery. Cases with per-
viety of the cerebral medial artery can surely offer a better prognosis.
Echo-Doppler examination of supra-aortic vessels is recom-
mended in patients who have undergone CE to monitor for recur-
rence, timing the follow-up examinations at 3 and 9 months after and 
every year thereafter.
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Medicine Anticipatory
D. Consoli, F. Galati, A. Vecchio

To compare the numbers reflecting the high incidence and preva-
lence of stroke brain with those of modest results obtained with drug 
therapy in secondary prevention, clearly highlights the importance of 
well-established primary prevention in reducing the risk of stroke. 
The percentage of outcomes of debilitating strokes in Italy is 40% of 
stroke accidents per year and corresponds to a number of about 70,000 
people. From owerview therapy and with an effective waiting on a
population of 2,400 strokes per million inhabitants, being in Italy cal-
culated the incidence of stroke around 2.4 per thousand, the number 
of events avoided defining the end point as death or dependance, is 
23 per million for the ASA (12 events avoided per 1,000 treated with 
a target population treatable 80%) of 34 for rt-PA <3 h (143 being 
the number of events per 1000 patients treated and 10% the number 
of potential patients who may require treatment) and 120 per million
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benefit from the shelter in Stroke Unit (50 events avoided per 1000 
hospitalized where 100% is the target population). It follows that, the 
best organization, we can have a benefit of 20% that, compared to 
the real world, can mean a decrease of 15% less, in absolute terms, 
the number of patients with serious outcomes. Hence the need for a 
ceiling is to decrease the number of stroke incidents. Prevention is the 
first reference to this goal.
Detect, monitor and treat risk factors is the most successful 
strategy in combating the stroke brain. In the Italian Health Service 
the general practitioner is the figure that more than any other can
perform this function for identifying and monitoring treatment. 
In recent years a general was prompted by the passage from the 
“medicine waiting” in which design should try to respond to
the needs of the patient, to the “anticipatory medicine” for which an 
early aggressive stance on risk factors, is expressed through “strategies 
mass” with the increase of healthy lifestyles, or through “individual” 
targeted at people with high risk (by convention> 20%). The anticipa-
tory medicine recognizes two methods of intervention: “The medical 
initiative” that sees its implementation in screening programs aimed 
at the population of early diagnosis and the consequent pre-emption 
(not required and not expected of course) and “medicine opportunities 
where screening and subsequent intervention takes the form prior to 
subjects that are addressed to the doctor for quite different reasons and 
not related to a stroke or any risk factors themselves. The latter repre-
sents the most effective and simple as it provides that in five years will 
see any doctor at least once all its patients. This methodology to be 
truly effective it will complement a motivational speech of the person
with whom there will be an education that will represent the therapy 
itself.
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Management & Leadership
M. Cecchi

The regional law N. 40 says that “hospitals have to be structured 
in differentiated areas in according to care modalities, intensity of 
care, length of stay, and type of hospitalisation, changing the sin-
gle discipline ward structure”. This model has been applied in our 
Azienda Sanitaria di Firenze since October 2007.
In our surgical department this view has lead to the use of a single 
ward with all surgical specialities but with similar intensity of care (at 
last in the most of cases).
One of the most controversial aspect of this re-engineering of the 
hospital circuit of the surgical patient has been the directors’ new way 
of considering “own ward, own nurses, own beds and so on”.
In our experience this critical aspect has been managed by stimu-
lating the new role of “leader & tutor of the patient” instead of “sim-
ply manager”.
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How to Prepare a Protocol for a 
Randomised Controlled Trial
S. Ricci, S. Cenciarelli, A. Barilaro, A. Mattioni, T. Mazzoli
UO Neurologia, Ospedale di Città di Castello, ASL 1 dell’ 
Umbria, , Italy
Why a busy physician should bother about randomised controlled 
trials (RCT)? Ideally, when we are faced with a patient, for whose 
condition or disease there is no proven treatment, we should offer 
participation in a clinical trial to solve both his or her problem and 
our uncertainty. Although frequently this is not the case, and we treat 
patients with procedures which have a very low level of evidence, we 
may well ask ourselves “why not to find out what is the best treatment 
for this disease?”. Then we will probably ask ourselves again “how 
can I do that?”. The answer is easy: we have to design and conduct 
a RCT.
It is impossible to describe here all the details related to the writ-
ing of a protocol for a RCT: we will just focus on a few strategic 
points.
The first step is to state what the objective is; it must be clear, it 
must be relevant, it must be one! Usually, we clinicians prefer qualita-
tive endpoints (dead or alive, new event or no event, etc.); however, 
sometimes it might be more appropriate to use quantitative endpoints, 
even with ordinal scales; for sake of simplicity, we will just focus here 
on qualitative endpoints. We need to know (from epidemiology, our 
experience or previous trials) what is the percentage of patients who 
“do badly” (that is, have the index endpoint) with our usual treatment; 
than, we need to establish what advantage we expect from the new 
treatment: it must be both clinically sound and credible. The decision 
on what degree of advantage is worth looking for should be taken in 
agreement with the health authorities and the patients’ organisations, 
whenever possible; the results should be able to modify the clinical 
practice, if we end up with a positive effect.
The second step is to calculate the sample size; we need to know 
whether we are actually able to recruit enough patients to answer the 
question we are asking; if we are not, either we change the question 
(or the degree of advantage, if clinically acceptable), or we add more 
centres to the study. To calculate the sample size, we need to know 
4 numbers: the percentage of patients with the endpoint in the con-
trol group (that is, those who do badly with the usual treatment), the 
possible absolute risk reduction (that is, the degree of advantage we 
want to see), the alpha error (that is, the probability we are ready to 
accept to say that something works when in fact it does not), and the 
beta error (that is, the probability we wish to accept to say that some-
thing does not work when in fact it works); usually, these two last 
figures are set at 5% and 20%, but may vary according to the clinical 
situation. Then the sample size can be calculated with a computer 
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statistical package (although we recommend to consult a statistician 
for more complex designs, for instance when the time to event is 
considered).
Just suppose that you end up with a number of patients you think 
you can recruit in a reasonable time (say, a couple of years); then you 
can start to prepare a detailed protocol, with a rationale, a list of inclu-
sion and exclusion criteria, and an explanation of the clinical evalua-
tion, both for inclusion and for follow up, as well as for the endpoint 
evaluation; all these steps should be as similar to the daily clinical 
practice as possible.
Do you need always a “double blind” design? We think you don’t. 
If the outcome measure is done by someone who is actually blind 
to the treatment, then there is no need to bother you and the patient 
with all the procedures related to blindness; if however the outcome 
evaluation may be influenced by the knowledge of the treatment, then 
blindness is necessary. In any case, you must ensure a very secure 
randomisation procedure (the so called randomisation concealment), 
which is the key factor to obtain comparable groups and trustable 
results.
25
Review of Different Thrombolytic Treatment 
Procedures: Intravenous, Intra-Arterial, 
Combined Intravenous and Intra-Arterial, 
Mechanical Including Thrombectomy or 
Stenting
R. Sztajzel

The benefit of intravenous thrombolysis with tPA has been dem-
onstrated within 3 hours of onset of cerebrovascular symptoms. 
When compared with placebo, patients treated within this time frame 
are 30% more likely to exhibit complete or nearly complete recovery 
at 3 months. Moreover, a recent study showed that there were more 
patients with a favourable outcome when treated with intravenous 
alteplase between 3 and 4.5 hours after onset of symptoms as com-
pared with placebo. As it has been shown in the PROACT II study, 
patients treated with intra-arterial thrombolysis (pro-urokinase, uro-
kinase or tPA) within a 6-hours window are also more likely to regain 
independency at 90 days than those assigned to placebo.
Furthermore, bridging therapies have been advocated with admin-
istration of systemic thrombolytics followed by infusion of intra-
arterial tPA to help dissolve clots. These combined intravenous and 
intra-arterial thrombolysis offer some advantages over either tech-
nique alone: intravenous treatment may be administered very early 
while the resources to deliver intra-arterial are organized; furthermore 
intravenous thrombolysis is easy of use and of widespread avail-
ability. On the other hand, intra-arterial thombolysis, as it has been 
suggested in several studies, may offer possible superior and earlier 
recanalization. Combined IV-IA thrombolysis has been studied in 
several trials.
Recent works emphasized on the potential role of mechanical 
thrombolysis, including thromboaspiration, percutaneous translumi-
nal angioplasty and implantation of stents, yielding recanalisation 
rates of more than 75% when intra-arterial thrombolysis is added. 
Other studies also demonstrated a potential benefit of a multimodal 
approach combining mechanical disruption and platelet GPIIb/IIIa 
receptor antagonists mainly as a rescue therapy after failure of intra-
venous or intra-arterial therapy.
The efficacy and safety of intravenous tirofiban combined with 
intra-arterial pharmacologic and mechanical thrombolysis has been 
evaluated in a cohort of 21 patients. Immediate recanalization was 
successful in 17 of them; however, intracranial bleeding occurred in 5 
of the 21 patients. Another study evaluated self-expanding stents for 
recanalization of acute cerebrovascular occlusions and showed that 
stent-assisted revascularization increased prevailing recanalization 
rates for vessel occlusions recalcitrant to thrombolytics.
26
Microbbubble-Enhanced Sonothrombolysis 
for Acute is Chemic Stroke
C.A. Molina
Unitat Neurovascular, Hospital Vall d’Hebron, Barcelona, 
Spain
Experimental and clinical studies have consistently demonstrated 
the capability of ultrasound (US) to enhance enzymatic thrombolysis. 
US application increases the transport of tPA into the thrombus, pro-
motes the opening and cleaving of the fibrin polymers, and improves 
the binding affinity of tPA to fibrin. In an observational pilot trial of 
combined therapy with 2-MHz continuous US monitoring and intra-
venous tPA in 55 patients with a documented MCA occlusion treated 
<3 hours of stroke onset, complete recanalization at 2 hours of tPA 
bolus was achieved in 36% of patients. In a small study using tran-
scranial color-coded sonography (TCCS), 32 patients were randomly 
allocated to be treated with combined TCCS and intravenous tPA or 
tPA alone <6 hours of symptom onset. Combined treatment was asso-
ciated with higher rates of recanalization but also with a higher rate 
of ICH. CLOTBUST, a phase 2 multicenter randomized trial, recently 
demonstrated that 2-hour continuous monitoring with 2-MHz TCD, a 
commercially available device widely used for diagnosis, in combi-
nation with standard tPA is safe and may improve outcome. Among 
126 patients randomized to tPA plus 2-hour TCD monitoring (target 
group) or tPA alone (control group), symptomatic ICH occurred in 
4.8% of target and 4.8% of control patients. Complete recanalization 
or dramatic clinical recovery at 2 hours after tPA bolus were observed 
in 49% of target and 29% of control patients (P = 0.02). Moreover, 
trends toward better clinical outcomes at 24 hours and long term were 
noted in sonothrombolysis patients. A phase 3 of the CLOTBUST trial 
is planned to begin in 2006. Enhancement of enzymatic thrombolysis 
by US may allow testing regimens with low-dose tPA to reduce the 
risk of ICH.
Microbubbles (MBs) are small air- or gas-filled microspheres 
with specific acoustic properties that make them useful as US con-
trast agents for sonographic examinations. In diagnostic US, MBs 
create an acoustic impedance mismatch between fluids and body tis-
sues, increasing the reflection of sound. Experimental studies have 
shown that US-accelerated thrombolysis may be further enhanced 
by administration of MBs. Low-frequency US with high power has 
been demonstrated to produce cavitation and fluid motion into the 
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thrombus.MBs, by acting as cavitation nuclei, lower the amount of 
energy needed for cavitation. Application of high-acoustic-pressure 
US has been shown to induce nonlinear oscillations of MBs, leading 
to a continuous absorption of energy until the bubbles explode, releas-
ing the absorbed energy.Thus, US-mediated MB destruction may fur-
ther accelerate the clot-dissolving effect of US.
The synergic effect of US and MBs on sonothrombolysis has 
been demonstrated in clinical studies in patients with arteriovenous 
dialysis graft thrombosis.However, whether MBs further acceler-
ate US-enhanced systemic thrombolysis in stroke patients remains 
unknown. Therefore, we sought to investigate the effects of galac-
tose-based MBs on the beginning, degree, and time to maximum 
completeness of middle cerebral artery (MCA) recanalization dur-
ing systemic thrombolysis and continuous 2-Hz pulsed-wave TCD 
monitoring.
We evaluated 111 patients with acute stroke attributable to MCA 
occlusion treated with intravenous tissue plasminogen activator (tPA). 
Thirty-eight patients were treated with tPA plus continuous 2-hour 
TCD monitoring plus 3 doses of 2.5 g (400 mg/mL) of galactose-
based MBs given at 2, 20, and 40 minutes after tPA bolus (MB group). 
These patients were compared with 73 patients who were allocated to 
receive tPA plus continuous 2-hour TCD ultrasound (US) monitoring 
(tPA/US group) or tPA plus placebo monitoring (tPA group), most of 
whom were enrolled in a previous study of US-enhanced thromboly-
sis. The beginning, degree, and time to maximum completeness of 
recanalization during the first 2 hours of tPA bolus were recorded. 
Median prebolus National Institutes of Health Stroke Scale (NIHSS) 
score was 18. Eighty patients (72%) had a proximal and 31 (28%) a 
distal MCA occlusion on TCD. Thirty-seven patients (33%) received 
tPA/US, 38 (34%) received tPA/US/MB, and 36 (32%) were treated 
with tPA alone. Stroke severity, time to treatment, location of MCA 
occlusion, and presence of carotid artery disease were similar among 
groups. Two-hour recanalization was seen in 14 (39%), 25 (68%), and 
27 patients (71%) in the tPA, tPA/US, and tPA/US/MB groups, respec-
tively (P = 0.004). Two-hour complete recanalization rate was signifi-
cantly (P = 0.038) higher in the tPA/US/MB group (54.5%) compared 
with tPA/US (40.8%) and tPA (23.9%) groups. The time to beginning 
of recanalization after tPA bolus was 26±18 minutes in the tPA/US 
group and 19±12 minutes in the tPA/US/MB group (P = 0.12). Four 
patients (3.6%) experienced symptomatic intracranial hemorrhage: 
2 (5.5%), 1 (2.7%), and 1 patient (2.6%) who received tPA only, 
tPA/US, and tPA/US/MB, respectively, experienced symptomatic 
intracranial hemorrhage. At 24 hours, 31%, 41%, and 55% of tPA, 
tPA/US, and tPA/US/MB improved >4 points in the NIHSS score. 
Administration of MBs induces further acceleration of US-enhanced 
thrombolysis in acute stroke, leading to a more complete recanaliza-
tion and to a trend toward better short- and long-term outcome.
27
CT Perfusion: Rationale in Acute Stroke 
Patients
G. De Berti
Dipartimento Diagnostica per Immagini ed Interventistica, 
Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
At present we have different therapeutic options in acute ischemic 
stroke, ranging from e.v. thrombolysis, sonothrombolysis, local intra-
arterial infusion of thrombolytic drugs, mechanical removal of the 
thrombus, mixed mechanical/farmacological strategies.
In any case the therapeutic window during which we can oper-
ate is a limiting factor as the result of reperfusion of an arterial dis-
trict is strictly dependent on its timing: as time passes by the less is 
the probability of recovery and greatest the risk of an haemorragic 
transformation.
Beside timing other elements to take into account during planning 
of a treatment are the site of occlusion, the nature of the occluding 
agent, the pathophysiological state of the involved brain parenchyma.
CT Perfusion (CTP) associated to a CT Angiography (CTA) study 
can give an answer to most of these questions.
Adding a few minutes (approximatively 10–15) to the acquisition 
of the basic standard brain CT we can obtain precious data regarding 
-the site and extent of arterial occlusion, -about the state of the col-
lateral pathways, -about the presence and extension of ischemia and 
–about viability of the affected tissues. CTP technique, in fact, can 
identify not only the extension of the ischemic territory in a very pre-
cocious time but also its pathophysiolocial state predicting the extent 
of tissue already irreversibly damaged and the extent of tissue at risk 
if not re-perfused, but still salvable. The results of numerous studies 
in the international literature and our own data confirm the high pre-
dictive value of this kind of information.
The great challenge to the neuroradiologist and to the stroke spe-
cialist is to clarify the proportion of dead/salvageable tissue (so called 
“mismatch” or core/penumbra) to consider for rationale treatment. 
Perhaps not only the respective volumes of core/penumbra are to be 
considered but we should also weight the “nobility” of the salvage-
able brain tissue.
Another outstanding advantage of CTP in acute stroke is the pos-
sibility to overcome the timing limitations in that it could help in 
choosing to treat a given patient even if the usual time window is 
passed-by or if we have no information about the time of onset (for 
example the so called awakening stroke); on the other hand we could 
decide not to treat a patient, even if a short time has elapsed since the 
onset of symptoms, should the CTP tell us that all the involved tissue 
is already irreversibly damaged.
The new generation of CT scanner permits today to obtain CTP 
and CTA acquisitions in a very short time, really adequate to patients 
that in the majority of cases are not or only partially cooperative.
This new generation of scanners, moreover, overcome the prob-
lem of the limited spatial coverage which characterized the old ver-
sions and permits to explore wide thickness of brain parenchima in a 
very short time.
The risks for the patients and adverse effects are really low: the 
total amount of contrast media infused for both CTP and CTA is simi-
lar to that used for a standard contrast brain CT; the X-ray exposure is 
well contained within the limits recommended for clinical use.
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Perfusional Studies in Acute Stroke
G. Malferrari*, M. Zedde*, G. De Berti°, M. Maggi°, 
A. Nucera*, A. Dallari*, E. Lotti*, N. Marcello*, F. Nicoli°
*Neurological Division and Stroke Unit, Arcispedale Santa 
Maria Nuova, Reggio Emilia, Italy; °Radiology Department, 
Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
The perfusional evaluation of the cerebral parenchyma in acute 
stroke patients has its main rationale in the distinguishing the por-
tion of brain tissue irremediably damaged and therefore non salvage-
able from the one ischemic but not irreversibly infracted and then 
salvageable by a rapid treatment. Such an approach is feasible and 
useful both in situations where no clear time of onset is disposable 
and in situation when the classical time window for thrombolysis 
is passed. Besides its usefulness is also well documented in acute 
stroke patients within the classical time window. There are several 
tools that can measure the perfusional status, both radiological and 
neurosonological, namely MRI with diffusion/perfusion software, CT 
perfusion and TCCS (Transcranial Colour Coded Sonography) with 
the administration of second generation contrast media and the use of 
non linear properties of interaction contrast-tissue of harmonic imag-
ing generation.
No direct comparison between these methods are disposable at 
our knowledge and the best method is not yet well defined. For prac-
tical reasons, MRI, although well studied and documented in the liter-
ature with the diffusion-perfusion mismatch definition, is not usable 
in many hospitals in an acute setting and the execution time or the 
not applicability in a significant portion of patients (pacemakers or 
metal prosthesis, heart disease with the poor tolerance of the supine 
position for a long time, significant decrease of blood oxygen satura-
tion in 20% of patients) limit the application of this technique. CT 
perfusion is a reliable and most practicable tool, with some techni-
cal limitations, as the limited brain volume examinable with a single 
contrast bolus, the use of iodinated contrast media (adverse reactions, 
impaired renal function) and the different performance of deconvo-
lution algorithm by operator expertise. Neurosonological techniques 
use the same mathematical rules than radiological methods and can 
measure perfusional parameters in a limited portion of brain tissue, 
namely a single oblique scaning plane in the axial access from tem-
poral bone window. This latter technique is markedly influenced by 
the suitability of temporal bone window, that is insufficient in 15% of 
patients, mainly in older patients and females and this feature is not 
overcame by contrast media use for the microvasculature examina-
tion. Therefore is not yet clear which are the threshold for hypoperfu-
sion in gray matter versus white matter and in the single restricted 
time window more and more away from symptom onset.
This approach can give a more attractive and physiological tool of 
evaluation in acute stroke but its practical use is actually in progress.
29
Neurological Functional Scales: National 
Institute of Health Stroke Scale (NIHSS), 
Modified Rankin Scale, Glasgow Scale
P. Nencini, M. Nesi
Stroke Unit, Carreggi University Hospital, Florence, Italy
Functional neurological scales, including NIHSS, Rankin scale 
and Glasgow scale, are routinely used in clinical practice and in ran-
domised controlled trials in patients with cerebrovascular diseases.
Functional scales are often utilized to standardize stroke severity 
in the acute phase, to describe functional variations, and to quantify 
improvementt.
NIHSS specifically assesses stroke severity while modified 
Rankin scale and Glasgow scale described handicap and disability, 
respectively. Furthermore the Barthel Index evaluates the ability to 
perform activity of daily living in order to draw and supervision the 
rehabilitative programs in stroke patients. The modified Rankin scale 
is worldwide used to assessed functional outcome in patients with 
stroke.
However a single scale describes only some features of the patient 
and stroke physician should take together all the information derived 
from different scales in order to describe the present and the future 
neurological status of every patient.
Only the routinely use of these scales in stroke care on clinical 
and research programs can ameliorate the whole clinical evaluation 
of stroke patient in order to select them to the most appropriate treat-
ment in the hyperacute phase and after.
30
Aspects Score
V. Palumbo
Department of Neurological and Psychiatric Sciences, 
University of Florence, Florence, Italy
In 1995 the National Institute of Neurological Disorders and 
Stroke rtPA (NINDS) study demonstrated the efficacy of systemic 
thrombolysis for the treatment of acute ischemic stroke when admin-
istered within 3 hours of symptoms onset. In the NINDS trial CT scan 
was used to exclude the presence of intracranial hemorrhage before 
randomization. There is now accumulating evidence that the presence 
of early ischemic changes (EIC) on CT can predict both functional 
outcome and the risk of intracerebral hemorrhage.
EIC identified on CT during the first few hours after stroke onset 
represent early cytotoxic edema and possibly the development of 
irreversible changes (the ischemic core). CT signs of early ischemia 
consist of sulcal effacement with loss of gray-white matter differen-
tiation in superficial cortical infarctions and subtle hypodensity of the 
basal ganglia in deep cerebral infarction. The role of extensive EIC on 
clinical prognosis has been observed in the ECASS trial, where the 
presence of parenchymal hypoattenuation exceeding one third of the 
middle cerebral artery territory was associated with increased mor-
tality and higher rate of hemorrhagic transformation. Given the low 
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reliability of the “one third” rule as an estimate of the extent of EIC, 
a standardised semiquantitaive CT grading system was validated in 
2001, the Alberta Stroke Program Early CT Score (ASPECTS).
For ASPECTS, which is calculated from two standard axial CT 
cuts (one at the level of the basal ganglia and one just rostral to the 
ganglionic structures), the territory of the middle cerebral artery is 
divided in 10 regions, with 1 point subtracted for an area of EIC within 
each of the defined regions. A normal CT scan has an ASPECTS of 
10. In clinical series of patients treated with systemic rtPA, the prob-
ability of dependence, death and symptomatic hemorrhage increases 
as the ASPECTS value decreases. An ASPECTS > 7 predicts a good 
functional outcome and a lower hemorrhagic risk.
In the NINDS study, patients with ASPECTS > 7 showed no 
treatment-modifying effect on good outcome, with a trend towards 
lower mortality at 90 days with rtPA and a number needed to treat 
of 5. Hence, there is currently no evidence for excluding patients for 
thrombolytic treatment within 3 hours based on the presence of EIC.
The use of a systematic approach becomes more relevant for 
patients treated beyond 3 hours, with the presence of extensive EIC 
(ASPECTS≤7) as a predictor of unfavourable outcome and high hem-
orrhagic risk. In the PROACT-II trial, which explored the efficacy 
of intra-arterial thrombolysis within 6 hours from onset, patients 
with ASPECTS > 7 were 3 times more likely to have an indepen-
dent functional outcome with thrombolysis compared with controls. 
In candidates to intra-arterial thrombolysis between 3 and 6 hours, 
the ASPECTS score, together with a rapid acquisition of evidence of 
vessel occlusion (with carotid ultrasound, CT angiography), can be a 
useful tool for selecting patients who are most likely to benefit from 
treatment.
A novel CT score, called posterior circulation-Acute Stroke 
Prognosis Early CT Score (pc-ASPECTS) has recently been tested 
in patients with vertebrobasilar ischemia. In the posterior fossa, the 
sensitivity for ischemic changes is improved with CT angiography 
source images rather than with non contrast brain CT scan. The pres-
ence of extensive EIC, quantified by a pc-ASPECTS≤7, may identify 
patients with basilar occlusion who are unlikely to have a favourable 
outcome.
Conclusion: ASPECTS is a topographic CT scoring system, that 
divides the middle cerebral artery territory into 10 regions. The base-
line ASPECTS value predicts functional outcome and symptomatic 
intracerebral hemorrhage. The scoring is simple and reliable and, 
beyond 3 hours, identifies stroke patients unlikely to make an inde-
pendent recovery, despite thrombolytic treatment.
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MRI: Brain Lesions in Ischemic Stroke
C. Carollo, R. Manara
UOC Neuroradiologia, Az. Ospedale Università di Padova, 
Padova, Italy
MRI offers a better (compared with CT) soft tissue contrast and 
multiplanar visualization of the ischemic area, but conventional imag-
ing (T1, T2 and FLAIR) usually do not identify the ischemic changes 
within the therapeutic window.
In recent years, diffusion weighted imaging (DWI) has been 
developed, allowing the recognition of cytotoxic oedema, which 
represents the first step towards the ischemic necrosis and appears in 
the very early few minutes from arterial occlusion as an area of mark-
edly increased signal intensity.
This sequence, based on echoplanar fast imaging, has the advan-
tage to be very sensitive and rapid (acquisition time about 30 sec-
onds) and can be coupled with perfusion MR studies, thus identifying 
the irreversibly damaged ischemic area and the hypoperfused one. 
The mismatch between these two regions can recognize the so called 
“ischemic penumbra”, i.e. the area that can be saved with a preco-
cious revascularization of the occluded artery.
MRI can also well recognize cerebral infarctions in the wather-
shed areas due to extracranial severe steno-occlusive disease, differ-
etiating between hemodynamic-hypotensive and trombotic strokes.
Moreover, specific MRI patterns may identify non occlusive 
infarcts due to hypoxiemia, hypoglicemia and metabolic enzymatic 
deficiencies, such as mitochondrial encephalopathies.
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Ultrasound Vascular Evaluation in the 
Acute Stroke: How to Perform an Intra and 
Extracranial Examination in Few Minutes
S. Castellani, F. D’Abate, I. Tanini
Institute of Internal Medicine and Cardiology, Department 
of Critical Care Medicine and Surgery, University of 
Florence, Florence, Italy
In patients with acute cerebral ischemia the clinician must select 
the optimal therapeutic strategy after careful consideration of differ-
ent treatment options according to the clinical presentation, the time 
of symptoms onset and all the different possible underlying obstruc-
tive mechanisms. Although according to SITS MOST the assessment 
of the vascular status is not mandatory to state the patient eligibility to 
systemic or intraarterial fibrinolysis, in clinical practice a timely vas-
cular diagnosis has proven to be a very valuable tool to make the best 
choice. The ultrasound vascular examination can effectively depict 
both the anatomical aspects and the functional characteristics of the 
cerebral and extracranial vascular compartments and can signifi-
cantly affect both the therapeutic decisions and the prognostic charac-
terization. Some typical examples are represented by the finding of an 
hemodynamic stenosis of the internal carotid stenosis in the presence 
of a TIA, the demonstration of a carotid dissection at the onset of sud-
den focal neurological symptoms, or an ultrasound demonstration of 
a extensive T occlusion of the internal carotid artery in a subject with 
stroke. All these different causes of obstruction imply different clin-
cal outcomes and require peculiar therapeutic options that must be 
well considered in addition to evaluating patient eligibility to fibrino-
lytic treatment. In experienced hands the neurosonologic evaluation 
(carotid Duplex, TCCD and TCD) has proved very useful to achieve 
a bedside diagnosis in this delicate clinical context, andis more suited 
than other precise and very sophisticated neuroradiologic techniques 
(angio MR, angio CT) for bedside examination in the emergency 
room. In fact US tests can be repeatad whenever needed according to 
the clinical fluctuations thus providing a real time continuous moni-
toring of the hemodynamic changes.
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The questions to be answered in evaluating an acute stroke patient 
are almost the same as during an examinaton routinely planned to rule 
out an atherosclerotic disease of intra/extracranial vessels, with only 
two main differences: should always be kept in mind: the first is that 
the test must be clinically oriented. For example in the presence of 
a left hemiparesis the first site to scan will be the right side internal 
carotid and middle cerebral arteries. The second main peculiar char-
acteristic is that the examination should be performed in not more 
than 15–20 minutes to avoid unacceptable delays in patient access to 
a fibrinolytic treatment (i.e. within the 3 hours therapeutic window).
The ability of TCCD and TCD to detect a vessel viability allows 
the monitoring of cerebral hemodynamics during the infusion of 
rTPA and can instantly demonstrate the persistence of an occlusion or 
the reopening of the artery even long time before a clinical improve-
ment. Therefore TCD monitoring helps to decide whether all fibrino-
lytic attempts should be interrupted or whether it may be necessary to 
shift to a more aggressive intra-arterial procedural revascularization 
by adjunct intra-arterial thrombolysis with low-dose rTPA infusion 
(the so called bridging protocol).
The carotid Duplex combined with TCD allows to establish 
whether the extracranial obstruction extends to the origin of the mid-
dle cerebral artery and/or anterior artery or if the intracranial perfu-
sion is preserved by intracranial activation of collateral compensatory 
pathways. The diagnosis of extracranial stenosis relies on both direct 
morphological visualization of the lumen reduction (2D echo in asso-
ciation with colordoppler and power-imaging) while the grading of 
the stenosis can be accurately determined by doppler velocity criteria. 
The focal acceleration (peak systolic velocity) should be measured 
after 60° angle correction at the level of maximum vessel lumen 
reduction where the velocity jet can be observed. The velocity in the 
internal carotid artery should than be compared to that found in a non-
stenotic segment of the common carotid artery. The cut-off point for 
a significant stenosis of the internal carotid artery is the finding of a 
gretear than 230 cm/sec peak systolic velocity and a greater than 3.5 
ICA/CCA peak velocity ratio. These criteria have been validated by 
parallel angiographic examinations and they have been published on 
Radiology in 2004. The proximal total occlusion of one of the major 
neck vessels can be directly diagnosed when the flow velocity sig-
nal is totally absent at color/power angio and conventional Doppler 
examination. The same criteria apply to total main stem MCA1 or 
ACA1 occlusions. When the blockage of the arterial lumen involves 
the more distal intracranial branches, the occlusion may not be 
directly visualized, but its presence can be indirectly inferred in the 
presence of an ipsilateral velocity reduction in one proxymal segment 
(>21% Zanette asymmetry index). Focal accelerations can also be 
found in intracranial arteries; they are consistent with lumen reduc-
tions whose severity can be accurately graded according to velocity 
indices as well. In conclusion an accurate neurosonologic character-
ization is fiseable in the patient with acute stroke and it is a tool of 
great utility both for the therapeutic decisions and for the near and 
long term follow up of the patients.
33
TCD and Cerebral Hemodynamics
G. Meneghetti
Department of Neurology University of Padova, Italy
Transcranial Doppler Sonography (TCD) is able to explore and 
monitor the cerebral hemodynamics regarding the study of move-
ments of blood and of the forces concerned in brain circulation. The 
evaluation of flow velocities (FV) as an index for cerebral blood flow 
(CBF) is based on the assumption that arterial diameter and several 
other hemodynamic parameters are stable during the period of mea-
surement. The normal condition for blood flow throughout most of 
the circulatory system occurs in long, straight blood vessels, under 
steady flow conditions. It is characterized by concentric layers of 
blood moving in parallel down the length of the vessel.
The highest velocity (V max) is found in the centre of the ves-
sel while the lowest velocity (V = 0) is found along the vessel wall. 
This gives rise to a parabolic flow profile. The disruption of laminar 
flow in the vessels leads to turbulence and increased energy loss. It 
occurs when flow velocities exceed a certain threshold value called 
Reynolds number (Re) which is defined by the following equation: 
Re  =  2rvρ/η
where r  =  vessel radius
v  =  flow velocity
ρ  =  blood density
η  =  blood viscosity
Therefore turbulent flow depends on flow velocity, on blood vis-
cosity and is consequent to a sudden change of the vessel lumen that 
can occur in the zones distal to stenotic arterial vessels, in arteries 
with tortuous course and at vessel branch points. The physical laws 
that determine steady laminar flow are also helpful in understanding 
in vivo cerebral hemodynamics, even though blood vessels are not 
rigid tubes and blood is not a perfect fluid but a 2-phase system of 
liquid and cells.
The application of Ohm’s law to cerebrovascular hemodynamics 
is reflected by the formula:
CBF  =  CPP/CVR
where CBF  =  cerebral blood flow
CPP  =  cerebral perfusion pressure
CVR  =  cerebrovascular resistance
This means that any change in CPP must be matched by a pro-
portional change in CVR, and vice versa, in order for CBF to remain 
constant: this mechanism is called “Cerebral Autoregulation”.
In cerebrovascular circulation most of the resistance is provided 
by the arterioles and their precapillary sphincters, while the basal 
cerebral arteries that form the circle of Willis play only a minor role. 
This implies that the vessels evaluated by TCD have a relatively con-
stant diameter and that the role of the arterioles in regulating CVR 
and therefore CBF is fundamental.
Consequently the velocities measured by TCD directly reflect the 
hemodynamic changes occurring in the vessel segment being stud-
ied. The diameter of the basal cerebral vessels are only insignificantly 
responsive to pCO2 while the resistance vessels are very sensitive to 
changes in arterial pCO2. Therefore the flow velocity can be assumed 
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to be proportional to CBF during CO2 testing. Variations in PaCO2 
are significant vascular modulator of CBF and the flow velocity rela-
tionship with PaCO2 is linear, with an approximately 4% change for 
every unit change in PaCO2. In conclusion TCD is a useful tool in 
exploring the cerebral autoregulatory mechanisms consequent to acti-
vation of collaterals (intracranial macrocirculation) and is also able to 
show the functional vascular reactivity of cerebral resistance arteries 
(intracranial microcirculation). Therefore TCD can be considered a 
qualified and reliable non invasive approach able to detect the vari-
ations of cerebral hemodynamics in a large variety of clinical and 
research settings.
34
TCD for Guiding Therapeutic Decision
C.A. Molina
Unitat Neurovascular, Hospital Vall d´Hebron, Barcelona, 
Spain
In the last few years, a tremendous progress and widespread 
implementation of noninvasive neurovascular techniques includ-
ing transcranial Doppler (TCD), computed tomography angiogra-
phy (CTA), and magnetic resonance angiography (MRA) have been 
achieved. These imaging modalities are being increasingly performed 
in the acute stroke setting without substantial delay in a large num-
ber of centers worldwide. Far beyond the simple demonstration of 
an intractranial artery occlusion responsible of patient´s neurological 
deficit, detection of arterial occlusion provides valuable prognostic 
information and may predict response to different reperfusion strate-
gies. Several studies have demonstrated that the absence of an intra-
cranial artery occlusion represents an independent predictor of early 
clinical recover and good long-term outcome. Conversely, persistent 
arterial occlusion predicts clinical fluctuations and early neurologi-
cal worsening. The location of arterial occlusion may represent a 
marker of clot burden and response to thrombolysis. So, the more 
proximal the occlusion the larger the clot. In a multicenter study 
including 253 acute strokes due to MCA occlusion, the probability 
of complete recanalization at 2 hours of tPA bolus varied depending 
on the location of MCA clot. Complete recanalization was achieved 
in 45% of patients with M2-M3, 29% of those with M1 and only 11% 
of patients with terminal ICA occlusion achieved a complete recana-
lization. Therefore, a rapid detection of clot location may be useful 
for selecting patients for more aggressive reperfusion strategies. On 
the other hand, in patients with basilar artery occlusion, the site of 
arterial obstruction may indicate the patho-physiologic underlying 
mechanism. While distal basilar artery occlusion suggests an embolic 
source, proximal occlusion basilar is in most cases the result of a 
complicated atherothrombotic plaque.
Transcranial Doppler ultrasound is a non invasive technique that 
uses ultrasound to obtain information of the flow velocity in the intra-
cranial arteries of the circle of Willis and vertebrobasilar system as 
a surrogate of the regional cerebral blood flow. In acute ischemic 
stroke, and particularly in the setting of stroke thrombolysis TCD 
provides rapid, reliable and real-time information on the presence 
and location of arterial occlusion and on recanalization at different 
times after stroke. Even continuous monitoring of the recanalization 
process can be done with TCD. The patterns of intracranial artery 
occlusion on TCD have been validated against conventional angi-
ography showing sensitivity and specificity values higher than 90%. 
The Thrombolysis in Brain Ischemia (TIBI) grading system has been 
developed to be applied rapidly in the acute stroke setting. These 
TCD grading system clearly reflects the dynamic nature of recana-
lization process during stroke thrombolysis and are based on the 
relative relationship between the insonation depth where the sample 
volume is placed and the clot location, so the closer the ultrasound 
bean to the thrombus the lower the TIBI score. Under good insonation 
conditions, an experienced operator can accurately identify the loca-
tion of the offending clot in few minutes (typically 2–4 minutes), and 
in patients with suboptimal windows it takes <15 minutes. Ultrasound 
testing can be performed at bedside simultaneously with neurological 
examination, vital signs monitoring, and drawing blood, causing no 
delay in tPA administration.
In the last five years, several TCD studies have improved our 
knowledge and understanding of the dynamic nature of the recana-
lization process during stroke thrombolysis. TCD provides a unique 
opportunity to assess several aspects of clot dissolution by means of 
continuous monitoring of recanalization during and after tPA admin-
istration. This approach allows us to evaluate at the patients bedside 
and in real time the beginning, timing, speed and degree of artery 
reopening as well as to document re-occlusion after successful recan-
alization. Moreover, the simultaneous clinical assessment during 
TCD monitoring permits to correlate the hemodynamic changes with 
the clinical course and outcome.
Several angiographic and TCD studies have shown that spontane-
ous recanalization is a frequent, but unfortunately, delayed phenom-
enon after acute ischemic stroke. While spontaneous recanalization 
occurs in only 13% of patients <6 hours of cardioembolic stroke, up 
66% of patients who receive tPA recanalized in the same time frame. 
tPA administration increases in 3- and 8-fold the rate of partial and 
complete recanalization, respectively. The time-to-artery reopening 
has been shown to be inversely correlated with clinical recovery and a 
time window of complete recanalization of <300 minutes from symp-
toms onset has been identify in human stroke to achieve full clinical 
recovery.
Recanalization is a continuous process that usually begins early 
after tPA administration. In most cases, recanalization occurs during 
the hour following tPA bolus, clot lysis starts at a mean time of 17 
minutes and ends at 42 minutes after tPA bolus. However, the time 
until complete clot dissolution and restoration of blood flow may 
vary widely, depending on location of occlusion, clot composition, 
area of clot surface exposed to blood flow, and pressure-driven per-
meation of tPA into the clot structures. Alexandrov et al described 
the patterns of the speed of clot dissolution during continuous TCD 
monitoring. Based on the time required to achieve the maximum 
completeness of recanalization, the speed of clot lysis is categorized 
in: Sudden (recanalization is defined as an abrupt normalization of 
flow velocities lasting seconds shortly after tPA administration), 
stepwise recanalization (progressive improvement in flow velocities 
lasting less than 30 minutes) and slow (progressive improvement in 
flow velocities lasting more than 30 minutes). Sudden recanalization 
reflects rapid and complete restoration of flow; stepwise and slow 
recanalization indicate proximal clot fragmentation, downstream 
embolization, and continued clot migration. Unlike in acute myocar-
dial infarction, the underlying pathophysiological mechanism of vas-
cular arterial occlusion in acute stroke is heterogeneous. Composition 
of cerebral embolic material may vary, depending on specific endo-
thelial and flow conditions of the embolic source. Old, platelet-rich, 
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and well-organized thrombi formed under flow conditions have been 
shown to be more resistant to thrombolysis than fresh, fibrin- and 
red cell–rich clots formed under conditions of stasis. Moreover, clot 
structure may differ depending on whether the embolic source is 
a thrombus engrafted in a proximal atherosclerotic lesion or a clot 
formed in cardiac cavities. In this context, stroke subtypes may rep-
resent a surrogate of the composition of offending clot. Our group 
demonstrated that in patients with proximal MCA occlusion treated 
with intravenous tPA, early recanalization is more frequent, faster, 
and more complete in patients with CE stroke. A cardiac source of 
emboli was identified in most patients who experienced sudden clot 
breakup during tPA administration. Sudden recanalization was asso-
ciated with a higher degree of neurological improvement and better 
long-term outcome than stepwise and slow recanalization. On the 
other hand, the presence of a concomitant ipsilateral severe carotid 
artery disease was associated with low MCA recanalization rate and 
poor clinical outcome. Cardioembolic stroke probably represents the 
stroke subtype with more uniform fibrin-rich clots. Given the high 
binding affinity of tPA for fibrin, in fibrin-rich clots, tPA penetrates 
and distributes homogeneously, leading to an entire and rapid clot 
dissolution (sudden recanalization). In contrast, in well-organized 
and platelet-rich clots, penetration and distribution of tPA are lim-
ited, which may result in non-uniform clot softening and degradation 
from the outside of the clot. As a result, the clot shrinks and moves 
distally, lodging in smaller arteries (stepwise or slow recanalization), 
which would prolong ischemia. This may explain the fact that the 
stepwise and slow patterns of recanalization were associated with a 
lower degree of neurological improvement and worse long-term out-
come than sudden recanalization shortly after tPA administration. The 
heterogeneity of clot composition is well illustrated in some patients 
with a documented MCA occlusion at arrival to the emergency room 
who experience a partial spontaneous recanalization before tPA bolus, 
but after treatment they remain with a persistent distal occlusion. This 
phenomenon may indicate that external fibrin-rich layer of the throm-
bus would be smooth enough to respond to endogenous fibrinolysis 
while the hard well-organized clot core would remain intact even in 
the presence of exogenous tPA (peach-like clot).
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Usefulness of the Ultrasound Contrast 
Media in Great Vessels and Microvasculature 
Examination of Brain
G. Malferrari*, M. Zedde*, A. Nucera*, A. Dallari*, 
E. Lotti*, N. Marcello*
*Neurological Division and Stroke Unit, Arcispedale Santa 
Maria Nuova, Reggio Emilia, Italy; °Radiology Department, 
Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
Ultrasound contrast media are microbubble –base moisture of 
different composition. First generation contrast agents are air filled 
bubble with a stabilized shell, but their size, durability and pressure 
resistance are not so favorable for the prolonged examination of cere-
bral vessels as echoamplificators for large vessels of the base of skull. 
Second generation contrast agents are gas filled microbubbles covered 
by lipidic and saccaridic shell, that guarantees a longer persistence in 
the bloodstream and a stronger resistance to pressure. Therefore sec-
ond generation contrast agents for ultrasound examination can offer 
some facilities in respect to first generation ones, both in large ves-
sel examination and in microvasculature examination. Then they can 
provide some advantages like as the harmonic generation and the non 
linear behavior of this feature can improve the visualization of small 
vessels and perfusional status in several situations, e.g. acute stroke, 
intracranial stenosis, vasculitides, moya-moya disease, brain tumors, 
brain hemorrhages, etc.
This approach has enlarged the spectrum of application of con-
trast media for ultrasound from its origin, i.e. the overcoming of 
insufficient temporal bone window.
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Differences and/or Analogies Between 
Coronary and Cerebrovascular Risk Factors
E. Melillo
U.O. Angiologia Universitaria, Dipartimento Cardio 
Toracico, Azienda Ospedaliero Universitaria Pisana, , 
Italy
Atherosclerosis is a systemic, chronic inflammatory process that 
mainly involves medium-sized arteries and affects the arteries of dif-
ferent vascular beds simultaneously, but with differing degrees of 
progression. Atherosclerosis tends to develop in the coronary arteries 
that supply blood to the heart, to the brain (the carotid, vertebral, and 
cerebral arteries) and the lower extremities (the iliac, femoral, popli-
teal and infra-popliteal arteries). Clinically, it can become apparent 
as ischemic heart disease, cerebrovascular disease, or peripheral arte-
rial disease. The presence of atherosclerosis in a particular vascular 
bed is frequently associated with disease in other vascular territories. 
The risk factors are the same for all affected vascular beds, regard-
less of location, and there is compelling evidence that established 
causal risk factors such as smoking, hypertension, diabetes mellitus, 
hyper-lipidemia play an important role in the development of vas-
cular disease. Although the exact mechanisms have yet to be clearly 
explained, causal risk factors promote the development of arterio-
sclerosis, predispose to coronary artery disease, act independently 
of one another and their effects are additive. There is also accumu-
lating evidence supporting the role of emerging risk factors such as 
hyper-homocysteinemia, protrombotic factors (fibrinogen, PAI-1) 
and inflammatory markers (C-reactive protein). Emerging risk factors 
are associated with an increased risk of ischemic heart disease, but for 
which a causal relationship has not been documented, because their 
atherogenic potential is lower and/or because their prevalence among 
the population is not high enough. Although all the risk factors favor 
the development of atherothrombotic disease in the different vascular 
beds, the predictive power of the risk factors differs from one territory 
to another. For example, the cholesterol level has a greater predictive 
power for the coronary territory, smoking for the peripheral vascular 
territory and hypertension for the cerebrovascular territory.
About the prognostic role of established risk factors, smoking is 
a powerful risk factor for all vascular diseases. A large number of 
epidemiological studies have clearly demonstrated that there is a lin-
ear relationship between cigarette smoking and the increased risk of 
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ischemic heart disease, stroke, peripheral arterial disease and sudden 
death. Cigarette smoking impairs flow-mediated endothelium-depen-
dent arterial vasodilatation, and, additionally, nicotine itself alters the 
structural and functional characteristics of vascular smooth muscle 
and endothelial cells. In addition, smoking favors atherothrombosis 
through multiple mechanisms, including endothelial damage pro-
duced by circulating carbon monoxide, increased fibrinogen and 
factor VII, increased platelet adhesion and aggregability, increased 
LDL oxidation, and decreased HDL-C concentration. Low-nicotine 
cigarettes increase cardiovascular risk to the same extent as the regu-
lar type. Even passive smoke exposure has a considerable effect on 
the flow-mediated vasodilatation and the risk of coronary heart dis-
ease in passive smokers is between 10% and 30% higher. Vice versa, 
the smoking cessation decreases by 50% the risk of coronary heart 
disease during the first year and approaches that of nonsmokers in 
two years. Smoking is associated with a variable magnitude of car-
diovascular risk, because the risk is highest for peripheral arterial dis-
ease and abdominal aortic aneurysm and lowest for cerebrovascular 
disease.
Hypertension is one of the major risk factors, independently of 
age, sex, or race. Arterial blood pressures, both systolic and diastolic, 
are correlated with the incidence of coronary heart disease and stroke. 
In a recent study of Tacoy et al, after evaluation of coronary segments, 
it was demonstrated that hypertension is associated with distal rather 
than proximal atherosclerosis of coronary arteries. A high blood pres-
sure is more than just a predictor of hemorrhagic stroke and a sys-
tematic review of 54 studies, by Cordonnier et al in 2007, showed 
that hypertension is a robust predictor (OR 3.9) of brain microbleeds, 
associated with both first-ever and recurrent ischemic and hemor-
rhagic stroke. Little is known about the role of hypertension in the 
atherothrombotic process: it has been postulated that the excessively 
high pressure would damage the endothelium and increase its perme-
ability. In addition, hypertension could stimulate the proliferation of 
smooth muscle cells or induce the rupture of the plaque. A number 
of clinical trials have demonstrated that a decrease in arterial blood 
pressure is associated with significant reductions in the rate of stroke 
and, to a lesser extent, in that of coronary events, circumstances that 
produce an overall decrease in cardiovascular mortality. Thus, reduc-
tions in diastolic arterial pressure of 5 mmHg reduce the five-year 
incidence of stroke by 34%, that of ischemic heart disease by 19% 
and that of cardiovascular mortality by 23%.
The association between hypercholesterolemia and the incidence 
of ischemic heart disease and/or peripheral arterial disease has been 
demonstrated in epidemiological studies. The relationship between 
cholesterol and ischemic heart disease is continuous, gradual and 
highly intense. The risk attributed to hypercholesterolemia is due to 
low-density lipoprotein cholesterol (LDL-C). A number of interven-
tion studies have demonstrated that the lowering of LDL-C by means 
of hypolipidemic agents (eg, with statins) is accompanied by signifi-
cant reductions in cardiovascular morbidity and mortality, both in pri-
mary and secondary care. Statin use in patients with peripheral arterial 
disease is also associated with an improvement in renal function and 
carotid intima-media thickness. An independent, inverse correlation 
between high-density lipoprotein cholesterol (HDL-C) and the risk 
of ischemic heart disease has been observed in several epidemiologi-
cal studies. The protection provided by HDL-C is independent of the 
LDL-C concentration. The National Cholesterol Education Program 
(NCEP) considers a HDL-C level below 40 mg/dL to be a risk fac-
tor, whereas concentrations over 60 mg/dL are reported to be a nega-
tive risk factor. An increased risk of ischemic heart disease of 3% 
to 4%, in the six-year, is associated with a decrease in HDL-C of 
1%. The HDL-C concentration correlates negatively with smoking, 
body weight and triglyceride concentration, and positively with fat 
and alcohol intake and physical exercise. There is no clear correlation 
between the concentrations of cholesterol and the incidence of stroke, 
although treatment with statins reduces the risk of stroke in patients 
with ischemic heart disease or with a history of previous stroke. 
Opposing results have also been published: in the Stroke Prevention 
by Aggressive Reduction in Cholesterol Levels (SPARCL) study, 
aggressive LDL-C lowering treatment with atorvastatin 80 mg/d 
in patients with a recent (1–6 months) stroke or transient ischemic 
attack was associated with an increase in the risk of hemorrhagic 
stroke (compared with placebo), but also with an overall significant 
decrease in risk of stroke and cardiac-related events.
Diabetes mellitus is associated with an elevated risk for ischemic 
heart disease and/or peripheral arterial disease and/or cerebrovascular 
disease, regardless of whether or not the individual is insulin-depen-
dent. Cardiovascular disease is the leading cause of death among dia-
betics. There is a direct relationship between the duration of diabetes 
in years and risk of ischemic heart disease. Type 2 diabetics present 
elevated cardiovascular risk which, on occasion, is similar to that of 
nondiabetic subjects who have experienced a coronary event. For this 
reason, the major guidelines consider diabetics to be subjects at high 
cardiovascular risk who should receive the same treatment as patients 
who have a history of a previous cardiovascular event. Diabetes mel-
litus favors atherothrombosis through a number of mechanisms: an 
unfavorable lipid profile (high triglyceride levels, low HDL-C lev-
els, small dense LDL particles), presence of modified LDL, hyper-
insulinism, hypercoagulability and increased inflammatory markers. 
However, surprisingly there is evidence of a negative association 
between diabetes mellitus and the development of abdominal aortic 
aneurysm. In a recent pilot animal study of Alnaeb et al, in 2007, 
were demonstrated differences in the regional distribution of eNOS 
activity, as well as ET-1 and 5HT receptors between the aorta, renal 
and femoral arteries obtained from control and diabetic rabbits: these 
regional receptors differences may explain why diabetes mellitus is 
linked with a predilection for atherosclerosis in distal arteries and not 
in the aorta of patients.
In conclusion, current data suggest that established risk factors 
are associated with specific vascular diseases with a variable mag-
nitude. These risk factors may also influence each other. Smoking 
is associated with high LDL-C, triglyceride and serum cholesterol 
levels, as well as low HDL-C concentrations. Smoking acts syner-
gically with other risk factors such as hypertension, hyper-lipidemia 
and diabetes mellitus, to increase vascular morbidity and mortality. In 
addition, smoking adversely influences several emerging risk factors 
(eg, fibrinogen and C-reactive protein). Family history may have an 
effect on the development of a specific vascular disease: the nega-
tive association between diabetes mellitus and abdominal aneurysm 
may support that a certain genetic background may be prone to the 
development of a specific vascular disease. Future studies may clarify 
the association between vascular risk factors and development of cer-
tain arteriopathies and may influence both prevention and treatment 
strategies.
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Cerebrovascular Reactivity, Endothelial 
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Elevated arterial blood pressure is strongly related with stroke, 
dementia, and silent cerebrovascular disease. Arterial hypertension, 
especially in the elderly, can lead to a shift to the left of the lower 
threshold of cerebral pressure autoregulation curve and it can reduce 
the CO2 dependent cerebral vasodilatation. On the other hand blood 
pressure normalization leads to a significant reduction in both isch-
emic and hemorrhagic strokes and in the prevalence of cognitive 
deterioration often found in hypertensives. Despite these well known 
associations, the intimate pathophysiological mechanism underlying 
the neuronal damage in elderly hypertensives is not fully understood. 
To investigate the hypothesis that hypertension can alter the auto-
regulation threshold not only at the lower end but also at its upper 
limit, and to evaluate the relation between cerebral vasomotion, endo-
thelial function and acute cognitive performance we have evaluated 
the cerebrovascular reaction to different adrenergic stimulations (i.e. 
pressor - handgrip, cognitive-fair culture test; ventilatory – 1 minute 
breath holding) in 5 groups (10 subjects/group): 2 groups of young 
and elderly healthy subjects; 2 groups of age matched (respectively 
young and elderly) systo-diastolic hypertensives, one group of elderly 
patients with isolated systolic hypertension. In all subjects, blood 
pressure increased significantly during handgrip and in the elderly 
hypertensive subjects, the pressure increase persisted during the 
recovery period. The pressure elevation caused a significant increase 
in mean flow velocity in the middle cerebral arteries (MCA) in the 
elderly and in young hypertensives (p<0.05), a slight though not sig-
nificant MCA velocity reduction in young normotensives (consistent 
with an autoregulatory vasconstriction), a slight though not signifi-
cant increase in MCA velocity in elderly normotensives. Cognitive 
stimulation significantly increased mean MCA blood flow velocity 
(p<0.001) and blood pressure (p<0.001) in all subjects. The velocity 
increase and the cognitive performance (FCT scoring) was signifi-
cantly higher in the young than in the elderly (p<0.001); the absolute 
velocity increase and FCT scoring were greater in young normoten-
sives than in hypertensives. Cerebral vasodilatation and cognitive 
performance was similar in both elderly groups. Mean MCA flow 
velocity rose less during FCT in young hypertensives than in age 
matched normotensives, and the FCT scoring was lower thus sug-
gesting a possible link between the sluggish cerebral hemodynamic 
response and the relative reduction in acute neuronal cognitive func-
tion. In elderly hypertensives, on the contrary, there was no evidence 
of a close neuronal-flow velocity coupling since the vasomotor reac-
tion to the cognitive stimulation was maintained but the cognitive 
performance (FCT scoring) was low. In all elderly hypertensives, the 
blood pressure elevation and the mean flow velocity increase persisted 
well into the recovery period, consistent with a defect of systemic 
blood pressure and cerebral pressure autoregulation. This defect of 
feed-back mechanisms can contribute to magnify the pressure burden 
on cerebral hemodynamics and explain the greater predisposition of 
the elderly hypertensives to cerebral damage, such as vascular cogni-
tive impairment or stroke. Breath holding increased mean MCA flow 
velocity by the same extent in all subjects thus indicating that oxygen 
dependent cerebral vasomotion is not affected by age or hyperten-
sion. Endothelial function was studied in all subjects by ultrasound 
evaluation of the changes in brachial artery internal dimensions after 
forearm transient ischemia (Flow Mediated Dilatation-FMD). FMD 
was significantly higher in young normotensives than in the other 
groups. In addition elderly ISH patients showed a reduced FMD con-
sistent with an impaired endothelial function compared with elderly 
normotensives (p 0.04). Nonetheless all elderly subjects showed sim-
ilar FCT scoring. In conclusion the ability of cerebral and systemic 
arteries to vasodilate in response to a cognitive or hypoxic stimulation 
are not related with acute cognitive performance. This results confirm 
the lack of correlation between maximum vasodilatation and cogni-
tion in elderly. Compared to the other groups significant differences 
were found in the elderly after adrenergic HG stimulation suggesting 
a reduced adaptability of cerebral perfusion to blood pressure oscil-
lations. These findings suggest that an altered cerebrovascular blood 
pressure autoregulation may be the mechanism underlying the greater 
prevalence of neural damage such as stroke and/or of vascular demen-
tia in aging subjects, especially in those affected by hypertension.
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Stroke in Patients with Coronary Artery 
Disease: Natural History and In-Hospital 
Events (Iatrogenic Morbidity in the 
Interventional and Cardio-Surgical Era)
S. Valente
, Florence, Italy
Stroke in the course of percutaneous coronary interventions 
(PCI) is fortunately a rare complication (0.27–0.5%), but neverthe-
less a devastating event for patients and caregivers. The incidence 
of stroke is greater in patients undergoing surgical coronary artery 
bypass graft (CABG). Stroke is considered to represent a periproce-
dural complication when occurring <24 hours following PCI, and is 
most commonly ischemic in etiology (cerebral hemorrage being con-
siderably less common). Its low incidence hinders the identification 
of predictive factors. Nevertheless, based on the available evidence, 
periprocedural stroke is more common is the elderly, in women, in 
patients with diabetes, chronic renal failure, diffuse atherosclerotic 
disease, and in those with other periprocedural complilcations (cor-
onary perforation, no reflow), intra-aortic balloon pump, or requir-
ing high doses of contrast medium. In patients with periprocedural 
stroke, in-hospital mortality is high as 27% at six months, as shown 
by the OASIS study. In this, as in prior studies, most cerebrovascular 
episodes occur in patients undergoing CABG, compared to PCI.
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State of the Art in Carotid Surgery
C. Pratesi, W. Dorigo, A. Settembrini, I. Spina, 
E. Giacomelli, A. Alessi Innocenti
Department of Vascular Surgery, University of Florence, 
Florence, Italy
The aim of current surgical approach (CEA and PTA and stenting) 
to cerebrovascular disease is essentially prophylactic against vascular 
ischemic stroke.
The high number of studies in literature and the analysis of inter-
national trials about the guidelines on carotid endoarterectomy make 
it right of the huge spread of such intervention: currently in vascular 
surgery it is the more widely performed intervention in the world. 
Recently the conceptual settings and methods of these trials were 
challenged, especially about the treatment of asymptomatic patients. 
It is argued that in these patients, the majority of stroke occurs on 
a cardioembolic basis or lacunar stroke. Therefore it is essential to 
identify patients with carotid plaque “at risk”, or those patients who 
have a high risk of stroke when treated in a conservative way.
If anatomic-pathological features of carotid lesions are known, 
still lacks the ability to identify in vivo and in a non-invasive way 
these lesions.
Some contributions in literature and two recent European multi-
center studies have identified the echocolordoppler as the tool that 
could identify the carotid plaque “at risk” on the basis of the assess-
ment not only quantitative but primarily of the quality of the mor-
phology of the lesion.
In literature have been proposed many types of classification 
of plaque that have generated some confusion. A recent consen-
sus, however, suggested that the evaluation of echogenicity should 
be indicated by the brightness of the plaque, dividing the lesions in 
hypoechogenic, isoechogenic and hyperechogenic, identifying the 
structures of reference: echogenicity of blood for hypoechogenic 
plaques, echogenicity of sternocleidomastoid muscle for isoecho-
genic plaques and echogenicity of bones of the cervical vertebrae for 
hyperechogenic plaques.
A further developement was obtained through the “normaliza-
tion” of the B-mode imaging that allows an objective and quantita-
tive study by reference to minimum gray scale blood and advential 
sheet. In this way the characterization is not expressed by an adjective 
but a number (GSM - Median Gray Scale), eliminating the variability 
caused by subjective interpretations and numerous classifications.
The relation between ultrasound morphological study of carotid 
plaque and immediate and late results of the procedure, surgical or 
endovascular, could allow to detect lesions that are expected of either 
treatment.
About this, the recent study ICAROS has shown that the peripro-
cedural risk undergoing carotid stenting increases significantly with 
the decrease of the echogenicity of the lesion. So the ideal lesions to 
be treated with endovascular procedure are those iso-hyperechogenic, 
that is full of fibrous tissue and calcifications and those with low 
lipidic and heamatic structure.
Therefore it is clear that the possibility to characterize with non-
invasive approach these components can potentially allow not only to 
identify the lesion at risk but also to choose which type of procedure 
is most appropriate in order to minimize the risk of intra and post-
procedural thrombo-embolic events.
Previous studies published by our group have enabled us to 
demonstrate statistically significant correlation between hypogenic 
plaque and appearance of omolateral neurological symptoms; simi-
larly hypoecogenicity of the lesion appeared related to the presence 
of silent brain lesions evaluated at CT scan. Moreover, in the plaque, 
the presence of large cholesterinic and haemorragic areas, assessed in 
an histological examination, were correlated with the appearance of 
ultrasonographic hypoecogenicity of the lesion.
In the last years we have also evaluated the preliminary results 
obtained with a new technique of ultrasonology called RULES (Local 
Radiofrequency Ultrasonic Estimator), based on elaboration of ultra-
sonographic signals at different radiofrequencies, which allows to 
have spectral parameters related to space and mechanical properties 
of the tissue examined and developed in a Laboratory of the Faculty 
of Engineering of University of Florence, lead by Prof.Leonardo 
Masotti, obtaining a good correlation between the histological data 
and those reported with ultrasonographic technique of radiofrequency 
in vitro.
In particular, was shown a correlation in 100% of the cases in 
identification of lipidic and calcific areas in the carotid plaque.
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Statins and Plaque Passivation
R. Abbate
Department of Medical and Surgical Critical Care, Unit of 
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The concept of plaque stabilization was proposed in the 1990s 
in an attempt to explain the discrepancy between a small amount 
of angiographically demonstrated plaque regression, and the large 
reduction in clinical events in trials of lipid-lowering drugs. “Plaque 
passivation” is a therapeutic concept by which either the structure 
or the content of the vulnerable and active atherosclerotic plaque is 
modified to reduce the risk of subsequent rupture and thrombosis.
The process of plaque destabilization begins with endothelial 
dysfunction against a background of inflammation. Postmortem 
pathologic studies have revealed that the vulnerable plaque has three 
hallmark histologic features: (i) a large lipid core occupying more 
than 40% of the plaque volume; (ii) an abundance of inflamma-
tory cells; and (iii) a thin fibrous cap that lacks proper collagen and 
smooth muscle cell support. In an unstable plaque, almost every cell 
type is activated. These cells are mostly monocytes–macrophages, 
but can also be activated T cells and mast cells. These inflammatory 
cells secrete certain enzymes (proteases) that degrade collagen. In 
addition, apoptosis of smooth muscle cells, which are the chief source 
of collagen, further weakens the plaque. The lipid core is composed 
of free cholesterol, cholesterol esters, and crystals. In addition, it con-
tains oxidized lipids, and is impregnated with tissue factor derived 
from macrophages, making it highly thrombogenic. The family of 
enzymes—matrix metalloproteinases (MMPs)—expressed by mac-
rophages erodes the thin fibrous cap resulting in exposure of throm-
bogenic subendothelial material to the circulating blood. The acute 
clinical event is precipitated by the formation of an intimal, platelet-
rich thrombus followed in some cases by a fibrin–red cell intralumi-
nal thrombus.
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The biology of plaque instability and rupture suggests that thera-
peutic strategies must revolve around three potential target sites: (i) 
platelets and the coagulation cascade leading to dissolution of the 
thrombus and restoration of luminal patency; (ii) passivation of dys-
functional endothelial cells for the reduction of pro-inflammatory 
and procoagulant activity; and (iii) modification of plaque contents 
by an aggressive reduction of serum low-density lipoprotein choles-
terol (LDL-c) levels and inhibition of LDL oxidation. These target 
sites are not mutually exclusive. Therefore, an integrated approach to 
plaque passivation in ACS is required to reduce future adverse clini-
cal events.
Based on evidence from human and animal studies, it can be 
assumed that lipid-lowering drugs stabilize plaque by several mecha-
nisms. Statin-mediated lowering of lipids may stabilize vulnerable 
plaque by changes in the lipid core itself. There is a reduction in the 
levels of oxidized LDL in the plaque’s core accompanied by reduc-
tion in plaque macrophage content, and increase in the volume of 
collagen and smooth muscle cells with statins. In a small, nonran-
domized study of patients undergoing carotid endarterectomy, statin 
therapy given for 3 months resulted in a decrease in the lipid pool 
and increase in fibrosis in carotid plaque. There was 75% less lipid 
core, 40% less oxidized LDL and MMP, and twice the amount of col-
lagen. In experimental studies, these changes require at least a few 
months to occur and, therefore, may not fully explain the early ben-
efits observed with statin therapy in patients with ACS.
Statins have “pleiotropic actions” that go beyond the lowering 
of LDL-c levels, and are relevant to the pathophysiology of ACS. 
In comparison to lipid-lowering actions, these pleiotropic effects on 
vascular and cardiac cells may be effective after early initiation of 
therapy. 
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A. Capalbo, N. Pucci, R. Pulli, C. Pratesi, G.F. Gensini, 
R. Abbate, B. Giusti
Department of Medical and Surgical Critical Care and 
DENOTHE Center, University of Florence, Italy;
Vascular Surgery Unit, Department of Surgery, University of 
Rome “Tor Vergata”, Rome, Italy;
Department of Surgical Sciences, University of Milano-Bicocca, 
Italy
Department of Vascular Surgery, University of Florence, Italy
Carotid artery disease (CAS) is the most frequently identified 
cause of ischemic stroke and is mostly due to atherosclerotic dis-
ease. Inflammation plays an important role in the pathogenesis of 
atherosclerosis.
Aims of this study were to investigate the systemic gene expres-
sion profile of patients affected by CAS versus control subjects, and 
validate and extend microarray data in two further independent popu-
lations of patients and controls.
Total RNAs were extracted from whole peripheral blood of 46 
patients affected by CAS and 46 controls comparable for age and sex. 
We determined the expression of 14,000 genes by two colors microar-
ray technology in n = 10 pooled RNA from patients and n = 10 pooled 
RNA from controls and validated data by real time PCR in n = 36 
CAS patients and n = 36 controls. 82 genes showed altered expres-
sion levels between CAS patients and controls: 61 genes resulted 
up-regulated and 21 down-regulated. Gene ontology analysis indi-
cated an alteration of the following biological processes: immune 
response, oxygen transport, cytoskeleton organization and lipidic 
metabolism. Some of the biological process found in CAS and the 
relative associated genes resulted similarly altered in patients affected 
by atherosclerotic lesions in an other district (abdominal aortic aneu-
rysm patients). In particular we focused our attention in validating 
genes associated with the biological process peculiarly observed in 
CAS patients. These genes encod for the major histocompatibility 
complexes, expressed by the human leukocyte antigens (HLA) or are 
involved in the immune response (HLA-DPA1, HLA-DPB1, HLA-
DQB1, HLA-DRB3, IFIT1, IGKV1D, TRBJ2-1, DBNL, HLA-B).
This study provides new insights into the regulatory mechanisms 
controlling the development and the progression of plaque emphasiz-
ing the central role of inflammatory and immune cells.
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Detrimental and Beneficial Effects of 
Ethanol by Stimulation of TRPV1 in 
Sensory Neurons
S. Materazzi, R. Nassini, S. Benemei, S. Castellani, 
P. Geppetti
Department of Preclinical and Clinical Pharmacology, 
University of Florence, Florence, Italy
The risk of coronary artery disease (CAD) is reduced by red wine 
and more in general by consumption of alcoholic beverages (Mukamal 
et al., N Engl J Med. 2003; 348: 109–18). However, the mechanism 
by which ethanol (EtOH) exerts protection is not fully understood. 
Ethanol stimulates neuropeptide-containing primary sensory neurons 
via the activation of transient receptor potential vanilloid 1 (TRPV1), 
also known as the capsaicin receptor, thus causing a burning sensation 
and the release of the neuropeptides, substance P (SP) and calcitonin 
gene related peptide (CGRP). TRPV1 belongs to a large family of ion 
channels and is gated by noxious heat (42–53ºC). Ethanol potentiated 
the response of TRPV1 to capsaicin, protons and heat and lowered the 
threshold for heat activation of TRPV1 from approximately 42ºC to 
approximately 34ºC. Thus, it is possible that ethanol-induced sensory 
responses that occur at normal body temperature (Trevisani et al., 
Nat Neurosci 2002; 5: 546–51). Recently we addressed the question 
as to whether ethanol may cause coronary vasodilatation by activa-
tion of TRPV1 on perivascular sensory fibers and the release of the 
vasodilating peptide CGRP. Indeed we observed that ethanol relaxes 
porcine isolated coronary and human isolated gastro-epiploic arter-
ies by TRPV1 stimulation and CGRP release. Ethanol by the same 
mechanism caused vasodilatation in the guinea pig coronary circula-
tion. Ethanol-induced release of vasodilatatory CGRP may contribute 
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to the reduced risk of CAD (Gazzieri et al., Cardiovasc Res. 2006; 
70: 589–99).
In addition to protective actions ethanol also contribute to vari-
ous diseases. In susceptible individuals ethanol is known to trigger 
attacks of asthma. We reported that ethanol contracts isolated guinea 
pig bronchi, via activation of TRPV1 on terminals of airway sensory 
neurons and releasing the bronchomotor peptide SP. This excitatory 
effect of EtOH, distinct from that of Acethilcoline, results also in neu-
rogenic inflammatory responses that may contribute to the mecha-
nism of EtOH-induced asthma (Trevisani et al., J Pharmacol Exp 
Ther. 2004; 309: 1167–73).
Alcoholic beverages, are not only cardioprotective, but they also 
trigger migraine attacks and activation of trigeminal neurons plays a 
role in migraine. We found that ethanol evokes release of neuropep-
tides from nerve terminals of the rodent meninges by TRPV1 stimula-
tion, thus provoking a vasodilatation that is abolished by the CGRP 
receptor antagonist, olgecepant, and is considered to be mediated by 
CGRP released from perivascular sensory nerve endings. Olcegepant 
has been reported effective in the treatment of the migraine attack. 
Thus, arterial vasodilatation of meningeal vessels by TRPV1 acti-
vation and CGRP release may be relevant to the mechanism by 
which alcohol ingestion triggers migraine attacks (Nicoletti et al., 
Cephalalgia 2008; 28: 9–17).
Finally, it is known that ethanol induces hemorrhagic gastric 
lesions in rodents, but the mechanism is only partly understood. A 
series of in vivo experiments in rats and mice (including neuroki-
nin-1 receptor deleted mice) showed that via stimulation of TRPV1 
in gastric nerve terminals, ethanol releases SP that activates epithelial 
neurokinin-1 receptors to generate damaging reactive oxygen species 
(ROS) and the highly reactive aldehyde 4-hydroxynonenal. We con-
clude that gastric lesions are caused by an initial detrimental effect of 
ethanol, which is damaging only if associated with TRPV1 activation, 
SP release from sensory nerves, stimulation of neurokinin-1 receptors 
on epithelial cells, and ROS generation (Gazzieri et al., Free Radic 
Biol Med. 2007; 43: 581–9). The present data indicate that the ability 
of ethanol to target TRPV1 may be associated to a series of detrimen-
tal effects, that range from production of a burning painful sensation 
to contributing to airway inflammation and migraine. However, it is 
possible that the neurogenic vasodilatation caused by ethanol in the 
coronary circulation contributes to the cardioprotective effect of mod-
erate alcohol consumption.
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Intrarterial Thrombolysis for Acute Ischemic 
Stroke
L. Valvassori, E. Botto*, A. Ciccone*
Dept. of Neuroradiology, *Stroke Unit, Ospedale Niguarda 
Ca’ Granda, Milano, Italy
Thrombolysis, in its broad sense of recanalization of a vessel 
occluded by thrombus, is probably the most challenging and promis-
ing therapy of acute stroke so far; it has the merit of having played 
a key role in changing the general perception of acute stroke, which 
switched from the mere contemplation of a bedridden patient to the 
consideration of stroke as a medical emergency.
The favourable results of the National Institute of Neurological 
Disorders and Stroke (NINDS) study on recombinant tissue plas-
minogen activator (rt-PA), a thrombolytic agent already used for 
myocardial infarction and pulmonary embolism, were followed by 
the approval of intravenous (IV) rt-PA for ischaemic stroke within 3 
hours from symptoms onset in 1996 in United States and three years 
later in Canada..
Albeit IV r-TPA is today the standard treatment for acute isch-
emic stroke, just 10–12% of the patients can be treated within 3 
hours, as IV rt-PA has many contraindications, and about 50% of 
those treated die or remain severely disabled. Hence, there is a need 
for other recanalizing treatments that are more effective and have 
less contraindications. IA thrombolysis might provide many advan-
tages compared to the intra-venous one, such as to titre the dosage of 
the thrombolytic agent, having high drug concentration locally and 
low in systemic circulation, facilitate clot disruption with mechani-
cal thrombolysis, extend the therapeutic time window and increase 
angiographic recanalization rates. For these characteristics IA in 
place of IV thrombolysis for acute ischemic stroke has been proposed 
for patients with severe neurological deficits, vertebrobasilar stroke, 
occlusion of major supra-aortic and cerebral arteries, presentation 
beyond 3 hours from symptoms onset, acute stroke caused by cervical 
artery dissection, recent surgical and invasive diagnostic procedures, 
pregnancy and anticoagulant therapy. However no data are available 
on the effectiveness of IA thrombolysis compared to the IV one that is 
known to be quicker to initiate, cheaper and easier to use.
Intra-arterial (IA) thrombolysis in acute ischemic stroke has a dif-
ferent story from the intravenous (IV) one. The first report was in 
1958 about a case of acute carotid thrombosis treated with IA plas-
mine but this approach was developed later with the diffusion of 
cerebral angiography and endovascular treatment. IA thrombolysis, 
indeed, was at first used to dissolve thrombi forming during cerebral 
angiography or endovascular procedures. The current procedure was 
introduced by Zeumer in 1982. It starts with an angiogram to identify 
the site of occlusion and collateral supply to the affected region. The 
guiding catheter is introduced percutaneously into the femoral, radial 
or brachial artery and advanced in the supra-aortic vessel of interest. 
A microcatheter is then positioned close to, or within the thrombus, 
allowing local thrombolytic agent delivery.
Thrombolytic agent may be aided by mechanical thrombus dis-
ruption through the manipulations of the microcatheter tip and mul-
tiple advancements of the microguide. In some cases an alternative 
strategy for thrombus removal is the use of mechanical recanaliza-
tion techniques such as percutaneous transluminal angioplasty with 
balloon catheters or clot extraction using retrieval devices. Also, 
specialised intravascular catheters that emit ultrasound, pressurised 
saline solution with resorption, or photoacoustic energy are being 
studied. Some of these devices have been created for other purposes 
and readapted to perform IA thrombolysis. Their risk to benefit ratio 
is still uncertain. The description of patients with complete or par-
tial early arterial recanalization during IA thrombolysis and early 
improvement of their neurological symptoms suggests the likely effi-
cacy of these techniques, but no substantive data exist.
For these purposes the Synthesis Expansion Trial has been 
designed, to compare IV thrombolysis with rtPA with IA thromboly-
sis (farmacological and/or mechanical).
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Most of ischemic strokes are due to thrombo-embolic events; 
angiographic studies on patients with acute ischemic stroke within 
8 hours from symptoms onset showed complete occlusion of a main 
cerebral artery in 80% of cases, mostly in the carotid territory. When 
angiography is performed within 12 hours from the event, in 80–90% 
of patients a stenosis or an occlusion matching with the neurologic 
deficit territory can be found . Therefore, the aim of the acute treat-
ment of a patient with severe brain ischemia is to early recanalize the 
occluded vessel and to restore brain perfusion in order to limit the 
extension of the ischemic core.
The studies about intravenous systemic thombolysis with rtPA 
in acute ischemic stroke showed that this therapy can improve the 
outcome if the infusion is performed within 3 hours from symptoms 
onset. However, systemic thrombolysis has strict inclusion criteria 
and its results are promising but not very satisfying. Locoregional 
intrarterial thrombolysis (LIT) has many advantages over systemic 
therapy:
1) intrarterial injection allows higher drug concentration inside 
the clot, therefore the farmacological efficacy is enhanced and the 
systemic activation of the drug is decreased.
2) thrombolytic injection can be joined with mechanical manoeu-
vres to fragment and aspire the clot.
3) dose of the thrombolitic drug can be set on the basis of the 
anatomical response (recanalization). The local infusion can be 
stopped at any time when the clot has resolved, limiting the deliv-
ered dose and the systemic concentration; otherwise, the administered 
dose with the systemic infusion is predetermined on the basis of the 
patient’s weight.
4) LIT allows a wider therapeutic window compared with sys-
temic therapy, because the treatment can be performed within 6 hours 
from symptoms onset in anterior territory stroke and 24 hours in case 
of vertebrobasilar stroke.
5) anatomical efficacy of the treatment can be evaluated during 
the procedure and the recanalization rate can calculated to assess and 
compare different techniques.
The main limit to the diffusion of LIT is the low number of pub-
lished studies on this topic, often with few patients enrolled, while 
most of observations have been reported outside randomized and 
controlled trials.
In only two randomized and controlled trials (PROACT I and II), 
LIT performed with rt-PA within 6 hours from symptoms onset has 
been compared with controls. A metanalysis of these trials showed 
that treated patients compared with control cases, had a reduction of 
the combined endpoint of death and 90 days dependence of 15% (OR: 
0.55, 95% CI 0.31–1.00); the hemorrhagic transformation rate was 
10% in the PROACT II (OR: 2.39; 95% CI 0.88–6.47). However, 
both studies only included patients with middle cerebral artery 
occlusion and did not allowed adjunctive mechanical manoeuvres. 
Another metanalysis that included different series and patients with-
out selected site of vascular occlusion, reported a good outcome in 
41.5% of treated patients vs. 23% of control patients (p = 0.002) and 
a mortality rate of 40% vs. 23% (p = 0.004); the symptomatic hemor-
rhage rate was higher in the group of the LIT patients (9.5% vs 3% ; 
p = 0.046). The outcome was influenced by the site of the occlusion, 
being better in the anterior than in the vertebrobasilar circulation. 
Overall, the results of clinical series report that the efficacy of LIT 
in the anterior circle varies from 30% to 70% and that the clinical 
outcome depends on the degree of recanalization; similar results are 
reported for the vertebrobasilar circulation.
Although these results are encouraging, LIT has some limitations:
Difficult recruitment of patients within the limits of the therapeu-
tic window, which appears still too short.
Increased incidence of hemorrhagic complications compared with 
systemic thrombolysis (10% versus 6.4%).
The clinical results depend on the arterial recanalization rate (a 
complete recanalization is obtained in only 30–40% of cases) and the 
reperfusion time.
When the flow has been only partially restored, reocclusion can 
occur.
For these reasons, industry and clinical research have been ori-
ented towards the project on new treatment modalities in order to 
enhance the effects of LIT. The main fields of interest are mechanical 
recanalization (by means of aspiration or fragmentation of the clot) 
and the association of LIT and systemic thrombolysis to improve the 
recanalization time and rate.
Mechanical thrombolysis is performed to reduce the thrombus 
burden and to obtain a faster recanalization, sometimes even imme-
diate. This approach has also the potential advantage to reduce the 
need of thrombolytic drugs and so to decrease the symptomatic hem-
orrhage rate. Therefore, a mechanical treatment can be performed 
even after 6 hours (depending on the series, within 8 hours). The 
most evaluated mechanical device is the Merci system, which allows 
to catch and extract the clot inside a guide catheter. This device has 
been evaluated in two randomized trials alone or in conjunction with 
pharmacologic LIT. In the last, the multimerci trial, 164 patients were 
enrolled and the recanalization rate was 54% with merci alone and 
69% with merci and rt-PA; the favourable outcome (m-RS 0–2) was 
39%. Interestingly, in patients treated with the new generation Merci 
device clinical results were improved; that underlines the continuous 
improvement of these devices. Other mechanical devices are avail-
able, but most of them have not evaluated in clinical radomized trials. 
A recent trial concerns the new device Penumbra, composed by an 
aspiration system and a thrombectomy device. Preliminary results are 
good, since recanalization rate (TIMI 2–3) was 85 %.
An other mechanical approach is intracranial angioplasty, that can 
now be more safely performed than in the past thanks to high com-
pliance balloons. In a series of PTA of the middle cerebral artery, a 
recanalization rate of 91% and m-RS of 73% were reported.
Recently, new attention has been oriented towards primary clot 
stenting, with or without simultaneous anti-GP IIb-IIIa injection. 
Actually this must be considered a bailout procedure but results are 
very promising.
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Indications, Techniques, Catheters for 
Mechanics Disobstruction. The Stents
M. Cellerini, S. Mangiafico

Indications to mechanical thrombolysis are mainly represented 
by an acute arterial occlusion with a high thrombus load (T siphon, 
Basilar artery) in a patient presenting out of the necessary time win-
dow (3–6 hrs) or with a wake-up stroke or after unsuccessful iv 
thrombolysis (bridging therapy). The most common techniques are 
constituted by clot suction with large bore microcatheter (21–35), clot 
retrival devices (Merci, IN TIME), clot fragmentation and aspiration 
(Penumbra) and soft angioplasty and stenting.
Our experience is mainly derived from the use of angioplasty and 
stenting in combination with asystemic glycoprotein (gp) IIb/IIIa 
inhibitor Tirofiban) in patients with acute basilar occlusion .
Outcome in acute ischemic stroke due to basilar artery (BA) occlu-
sion remains poor with high mortality or severe disability, despite the 
proliferation of numerous endovascular techniques. In patients with 
stroke due to BA occlusion a wider time window acute intervention 
is allowed, because of the poor prognosis and the progression of 
symptoms. We assessed the hypothesis that an intra-arterial approach 
with primary stenting combined with systemic glycoprotein (gp) IIb/
IIIa inhibitors is feasible and might lead to high recanalization rates. 
We retrospectively reviewed 23 consecutive patients with acute BA 
occlusion, treated with intra-arterial approach at the Careggi Hospital 
(Florence, Italy) from February 2004 to May 2008. We evaluated the 
recanalization rate using the Thrombolysis in Myocardial Infarction 
(TIMI) score and 3 month outcome using the modified Rankin scale 
(mRS) in patients treated with primary basilar stenting and gp IIb/IIIa 
inhibitor tirofiban, compared with intra-arterial thrombolysis with 
urokinase and/or mechanical disruption.
Nine patients (45% male, mean age 62 ± 16 years, median NIHSS 
27) were treated with intracranial stenting and gp IIb/IIIa inhibitors 
and 14 patients (78% male, mean age 70 ± 15 years, median NIHSS 
26) were treated with intra-arterial urokinase and/or mechanical dis-
ruption. Eight out of 9 (89%) patients treated with stenting had recan-
alization of BA (TIMI 2–3), versus 10/14 (71%) of patients treated 
with urokinase. Complete recanalization (TIMI 3) was achieved in 
67% of patients treated with stent versus 14% of subjects treated 
with urokinase. Good outcome (mRS 0–3) rate in the stenting group 
was similar to the urokinase group (33% versus 28%, respectively). 
Mortality rate was higher in the stenting goup (44% versus 36%). 
One symptomatic hemorrhage was observed in the urokinase group.
Conclusions In our series, the approach with systemic adminis-
tration of gp IIb/IIIa antagonists and placement of intracranial stent 
appears to be feasible and safe, reducing the use of thrombolytic 
agents. The high recanalization rate obtained with this procedure 
makes this approach promising. More data are needed to confirm the 
efficacy of this treatment.
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National Organization of Stroke Assistance
M. Rasura, F. Biraschi
II Facoltà Medicina e Chirurgia, Sapienza Università Roma, 
Azienda Ospedaliera S. Andrea, Roma, Italy 
Regarding all the interventions directed to the reduction of death 
and disability following a stroke, it was demonstrated that a early 
recovery in a dedicated unit, a Stroke Unit, determines an absolute 
reduction of the risk of dead/dependency of 5.6%; practically for every 
1000 patients admitted in Stroke Unit, 56 avoid died/dependency.
In order to make a correct evaluation of the “stroke question”, it 
is important to know the data of prevalence and incidence in western 
countries.
Prevalence increases with age. In international population-based 
studies, prevalence reaches values between 4,61 and 7,33 for 100 
inhabitants in the subjects older than 65 years.
In Italy available data are from the Italian Longitudinal Study on 
Aging (ILSA) (1), that refers to a population between 65 and 84 years. 
Among this population the prevalence rate is a 6,5% (IC95: 5,8–7,2), 
with an higher prevalence rate in male (7,4%; IC95: 6,3–8,5) than the 
female (5,9%; IC95: 4,9–6,9).
In other European population-based studies with a similar meth-
odological approach, the incidence rate
was 8, 72 per 1·000 (IC95: 7, 47–10, 06) in subjects between 65 
and 84 years.
These data reveal that we are in front of a real “stoke epidemia” 
and that it needs structural and coordinated interventions both at 
regional and national level. Considering even the severity of strokes 
(110,000 strokes per year and 230,000 those with disability from pre-
vious stroke) it has become indispensable to make an operative reor-
ganization and to promote the idea that stroke is a curable medical 
emergency. It is also necessary to stimulate the prompt beginning of a 
correct secondary prevention.
On the epidemiological data shown, that characterize stroke like 
one of the main causes of dead, the following interventions should be 
adopted:
Prevention in the general population
– Health education programs
– Programs to aware of the stroke question the General Medicine 
Doctors
– Emanation of specific regional guidelines. Useful for technical, 
methodological, and organizational support for the Local Sanitary 
Companies, based on the national guidelines (SPREAD).
Prevention in high risk individuals
– To improve the identification of individuals at greater cardio-
vascular risk
– To guarantee the therapeutic continuity to the high risk patients 
both with pharmacological and non-pharmacological strategies, 
according to the international guidelines.
– To improve the accessibilty to the early intensive units and then 
to the follow-up and post event programs.
Improvement of the organizational efficiency and effectiveness
– To help the early admission, in specialized units possibly, of the 
stroke patients in order to facilitate the prompt institution of specific 
CED26(S2).indd   28 2008-11-11   21:48
Cerebrovasc Dis 2008;26(suppl 2):1–30 29Abstracts of the 17th National Congress of 
the SINV, Montecatini Terme, 2008
therapies such as pharmacological or sugical re-vascolarization in 
ischemic stroke or neurosurgical evaluation in the hemorragic.
  
All this is possible by the institution of the Stroke Unit that syn-
thetizes how much was previously debated.
A Stoke Unit is:
1. a ward that admit patients with acute stroke (within 48 h)
2. presence of beds dedicated exclusively to the cure of patients 
with acute stroke ( at least 80% )
3. staff (doctors and nurses) dedicated exclusively to the cure of 
the patients with stroke (at least a doctor or nurses occupied for 80% 
of their working hours).
From the experiences matured up to now in international and 
national contest, characterizing points for a SU are:
– multi professional integration
– early rehabilitation
– staff education
– particular attention to the communication with the patients, their 
relatives and with the doctors of general medicine.
– engagement to guarantee a continuity in the cure and the 
attendace.
The chance to have a continuous monitoring of vitals sign (Blood 
pressure, heart rate, temperature) leads to a better surveillance of the 
patient in the acute phase and characterizes the intesive-subintensive 
type of stroke unit.
The stroke unit must be integrated with all the other units that are 
involved with the management of the patient during his acute phase. 
It must also be opened to the territory of competence, through the 
collaboration with the general medicine doctors and with Local the 
Sanitary Company and the Districts to the aim to guarantee the dimis-
sioni protette and the programs of rehabilitation and reinsertion of 
the patient.
The implementation of the subintensive dedicated units 
(Stroke Unit) represent a part of a more wide process that tends to 
guarantee the best management for the patients and the therapeutic 
continuity.
This must be carry out even by the integration with the territory, 
the rehabilitation structures, the ambulatorial activity of follow-up 
and secondary prevention.
The objective is to realize the standardization and the adaptiation 
of the regional welfare levels as well as the correct distribution of the 
human and technological sources in order to answer in the right way 
to the Stroke Emergency.
 
(1) The Italian Longitudinal Study on Aging Working Group. 
Prevalence of chronic diseases in older Italians: comparing self-
reported and clinical diagnoses. Int J Epidemiol 1997; 26: 995–1002.
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